Discovery and Development of Small-Molecule Modulators for the Sulfation of Glycosaminoglycans and Studying the Role of O-GlcNAc on CREB through Semisynthesis by Cheung, Sheldon Ting Fong
 
DISCOVERY AND DEVELOPMENT OF SMALL-
MOLECULE MODULATORS FOR THE SULFATION OF 
GLYCOSAMINOGLYCANS 
and 
STUDYING THE ROLE OF O-GLCNAC ON CREB 
THROUGH SEMISYNTHESIS 
 
 
Thesis by 
Sheldon Ting Fong Cheung 
 
In Partial Fulfillment of the Requirements for 
the degree of 
Doctor of Philosophy 
 
 
CALIFORNIA INSTITUTE OF TECHNOLOGY 
Pasadena, California 
 
2017 
(Defended September 22, 2016)
 ii
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2017 
Sheldon T. Cheung 
All Rights Reserved 
 iii
ACKNOWLEDGEMENTS 
First and foremost, I would like to thank my advisor, Prof. Linda Hsieh-Wilson, for 
her support and guidance throughout the whole process. Without Linda, I would not have 
been able to work on such amazing research and accomplish the work reported here. She 
challenged me to be the best scientist possible and I would not be the scientist I am today 
without her direction. I would also like to thank my committee members, Prof. Bil Clemons, 
Prof. Peter Dervan, and Prof. Dennis Dougherty. Their scientific advice and support 
throughout my time here have also been instrumental to my success. Additionally, I would 
like to thank all Hsieh-Wilson lab members, past and present. I have been lucky to have such 
great colleagues to work with every day that can give day-to-day help and make the graduate 
school process that much more enjoyable. I would also like to thank my family: my mom, 
dad, brother Sab, sister Liv, mother-in-law Lai-Yoong, father-in-law Chee-Pun, and sister-
in-law Xiao-Xiang. They have all not only been supportive of my studies 3,000 miles away, 
but have been part of a support network for all parts of my life as well. Last, but certainly not 
least, I would like to thank my wife Xiao-Lan and son Lewis. They are everything in the 
world to me and their loving support was what truly allowed me to get through this trying 
process. 
 
 
 
 
  
iv
ABSTRACT 
Glycosaminoglycans (GAGs) are sulfated polysaccharides that play key roles in 
many cellular processes, ranging from viral invasion and cancer metastasis to neuronal 
development. Their diverse biological activities stem from their complex sulfation patterns, 
which are tightly regulated in vivo. For instance, the GAG chondroitin sulfate (CS) has been 
shown to undergo regiochemical sulfation during development and after spinal cord injury. 
However, few tools exist to modulate specific GAG sulfation patterns and study their 
importance in different biological contexts. Here, we identified the first cell-permeable small 
molecule that can selectively inhibit GAG sulfotransferases and modify the fine structure of 
GAGs. We demonstrate that the inhibitor reduces GAG sulfation in vitro and in cells and 
reverses CS-E-mediated inhibition of neuronal outgrowth. This small molecule may serve as 
a useful lead compound or chemical tool for studying the importance of CS and other GAGs 
in normal biology and disease.    
The β-N-acetyl-D-glucosamine (O-GlcNAc) post-translational modification plays a 
major role in many diseases such as cancer, diabetes, and neurodegenerative disorders, but 
much is still unknown about its molecular-level influence on protein structure and function. 
Although post-translational modifications have been known to induce important structural 
changes in proteins, notably, no structures of O-GlcNAcylated proteins exist. The challenge 
of obtaining homogeneous glycoproteins bearing the GlcNAc sugar at defined sites has 
hindered the structural and biochemical studies of this modification. Here we have utilized a 
semisynthetic approach to generate a homogeneously O-GlcNAcylated form of cyclic-AMP 
response element binding protein (CREB) for structural and functional studies. 
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INTRODUCTION TO GLYCOSAMINOGLYCANS AND THE ROLE OF 
SULFATION 
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C h a p t e r  1  
INTRODUCTION TO GLYCOSAMINOGLYCANS AND THE ROLE OF 
SULFATION 
Glycosaminoglycans (GAGs) are a large class of polysaccharides that decorate cell 
surface proteins or exist as part of the extracellular matrix. They play a myriad of roles in 
different cellular processes, including viral invasion,1,2 cancer metastasis,3-5 neuronal 
development,6,7 and spinal cord injury.8,9 Their diverse biological activities stem from their 
complex and heterogeneous structures, which allow them to interact with a wide range of 
proteins. GAGs are long, linear polysaccharide chains composed of repeating disaccharide 
units that display various patterns of sulfation. Their length can vary from 20-200 
disaccharide units and contain areas of low to high sulfation. It has been established that 
specific GAG sulfation motifs are key structural determinants in regulating protein 
recognition and downstream signaling. However, while nature chose to exploit GAG 
heterogeneities to mediate distinct cellular functions, these same heterogeneities have 
complicated our ability to study their specific biological roles. The study of GAGs would 
greatly benefit from the development of new tools, particularly small-molecule modulators, 
to help dissect the molecular properties that elicit these different biological functions. 
 
Types of Glycosaminoglycans  
There are three major sulfated classes of GAGs: heparin and heparan sulfate (HS), 
chondroitin sulfate (CS) and dermatan sulfate (DS), and keratan sulfate (KS). These three 
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Figure 1.1. Structures of the major classes of sulfated glycosaminoglycans.   
families of GAGs have various biological functions despite only subtle differences in their 
macromolecular structures (Figure 1.1). All of these GAG structures are found linked to a 
proteoglycan core bound to the cell membrane or secreted into the extracellular matrix 
predominantly via O-linkages to serine or threonine residues. KS is the one exception that 
may also be found linked via N-linkages to asparagine residues.10-12 
 
 
 
 
 
 
 
 
 
 
Heparin and HS, the most well studied class of GAGs, are particularly important in 
anticoagulation,13 cell growth and development,14 angiogenesis,15 and viral invasion.1,2 They 
are made up of disaccharide units containing N-acetylglucosamine (GlcNAc) and glucuronic 
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acid (GlcA) or iduronic acid (IdoA). Despite sharing the same structural components, the 
classification between heparin and HS is derived from their overall composition. Heparin, 
produced only by mast cells, exists as a shorter polysaccharide (10-12 kDa) compared to the 
ubiquitously expressed HS (10-70 kDa). Additionally, while the presence of IdoA 
predominates in heparin (>70%), GlcA represents the majority of uronic acid content in HS 
(50-70%). Another important distinction comes from the sulfation of the two types of 
molecules. HS contains an average of ≥1 sulfate groups per disaccharide, while heparin 
contains about ~2.7 sulfate groups.12 Due to the amount of sulfate groups, heparin possesses 
the highest negative charge density of any known biological macromolecule.  Heparin and 
HS also share the same positions in which sulfation or acetylation can occur: sulfation at the 
3-O and 6-O of GlcNAc, sulfation of the 2-O of GlcA or IdoA, and N-sulfation or N-
acetylation. Comparative analysis between heparin and HS has shown that the N-sulfation 
frequency is much higher (>80%) and the concentration of O-sulfated groups exceed that of 
N-sulfated groups in heparin.16     
The next family of GAGs, chondroitin sulfate and dermatan sulfate, have intriguing 
functions in numerous cellular processes, including neuronal development,6 spinal cord 
injury,8 growth factor signaling,17 morphogenesis,18 and cell division.19 CS is comprised of 
disaccharide units containing GlcA and N-acetylgalactosamine (GalNAc), while DS 
disaccharide units are made up of IdoA and GalNAc. Despite having different uronic acid 
content, these two GAGs are classified in the same family because they share a similar 
biosynthetic pathway and linear polysaccharides often exist as co-polymers of both 
structures.11 Sulfation is specifically localized to three hydroxyl groups, the 2-O of the uronic 
acid and the 4-O and 6-O of GalNAc. Defined combinations of these sulfate groups give rise 
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to the four major sulfation patterns: CS/DS-A, -C, -D, and –E (Figure 1.2). Expression of 
these different motifs often changes throughout development and disease and has been 
shown to molecularly facilitate different binding surfaces for interacting proteins.20,21        
 
 
 
 
 
 
KS, the last type of sulfated GAGs, has mainly been studied as a functional 
component of cornea, cartilage, and bone tissues. Changes to KS expression in the cornea 
have profound effects in diseases such as macular corneal dystrophy and keratoconus.10 
Moreover, recent studies have also implicated KS in the inhibition of neural plasticity after 
spinal cord injury.9 KS polysaccharides are linear polymers of lactosamine, made up of 
galactose (Gal) and GlcNAc monosaccharides. Sulfation of KS has only been found to occur 
at the 6-O position of either Gal or GlcNAc, limiting its diversity as compared to heparin/HS 
and CS/DS. However, a unique feature of KS is its expression as both an N-linked (KS I) 
and O-linked glycan (KS II).  
 
CS-A CS-C 
CS-D CS-E 
Figure 1.2. Four major sulfation motifs of chondroitin sulfate (CS). 
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Biosynthesis of Glycosaminoglycans 
The biosynthesis of GAGs involves the action of a variety of different Golgi-bound 
glycosyltransferases and sulfotransferases. Their activity leads to the appendage of an 
oligosaccharide linker onto the protein core, polymerization of disaccharide units, and 
specific sulfation of hydroxyl groups. By targeting these enzymes, studies have established 
the important roles of GAGs in different biological contexts and diseases. Therefore, 
modulation of these biosynthetic enzymes is of great interest in the pursuit of therapies for 
many illnesses.   
Heparin, HS, CS, and DS biosynthesis initiates with the attachment of a 
tetrasaccharide linker region onto the core protein. This tetrasaccharide is always composed 
of GlcA-Gal-Gal-Xyl. Xylose (Xyl) is first appended to the core protein by the action of one 
of two xylosyltransferases, XylT1 or XylT2. Two Gal monosaccharides are then added 
sequentially by the galatosyltransferases GalT-1 and GalT-2, respectively. Lastly, 
completion of the linker is performed by the addition of GlcA by the GlcAT-1 enzyme. 
Besides genetic methods, this linker region can be taken advantage of to study GAGs by 
using β-xylosides as a way to prime GAG synthesis and compete with the endogenous 
protein bound Xyl.22-24  
At this point, heparin/HS and CS/DS biosynthesis diverge by the addition of the 
GlcNAc or GalNAc, respectively, onto the tetrasaccharide linker. In heparin/HS 
biosynthesis, the family of exostosin-like glycosyltransferases (ExtL1, ExtL2, ExtL3) is 
responsible for the initiation of polymerization by the attachment of the GlcNAc residue.  
After this initiation, a heterodimer of the exostosin glycosyltransferases Ext1 and Ext2 
  
7
polymerizes the rest of the polysaccharide. Deacetylation and sulfation can then begin on 
the growing polymer through the catalysis of N-deacetylase/N-sulfotransferase (Ndst). This 
is followed by epimierzation of GlcA to IdoA by C5-epimerase. Further sulfation of the 2-
O, 3-O, and 6-O positions of the disaccharide can then occur through the activity of the 
heparan 2-O-, 3-O-, and 6-O-sulfotransferases (Hs2st, Hs3st, and Hs6st). These 
deacetylation, sulfation, and epimerization steps of GAG chains are not found to be 
performed to completion, thus leading to heterogeneity in the polymer.25-27  
CS/DS synthesis is triggered by the addition of GalNAc by N-
acetylgalactosaminyltransferase-I (GalNAcT-I) to the core tetrasaccharide (Figure 1.3). 
Further elongation occurs with chondroitin synthetase (ChSy), a protein complex containing 
GalNAcTs, glucuronosyltransferases (GlcATs), and chondroitin polymerizing factor 
(ChPF). It has been shown that impairment of these chain polymerizing enzymes leads to the 
skeletal abnormalities such as chondrodysplasia, decreased bone density, and digit patterning 
defects. At this point, DS-epimerase can convert GlcA monosaccharides to IdoA and 
generate the DS disaccharide. However, like heparin and HS biosynthesis, this step is often 
substochiometric leading to a linear polysaccharide with a mixture of GlcA and IdoA. On 
the polymerizing chain, sulfotransferases can then begin to differentially sulfate the 2-O 
position of GlcA or 4-O and 6-O positions of GalNAc. In CS/DS synthesis, there are distinct 
enzymes involved in the generation of each sulfation motif.  As such, the synthesis of the 
CS/DS-A and CS/DS-C units by chondroitin/dermatan 4-O-sulfotransferases (Chst11-14) 
and chondroitin 6-O-sulfotransferase (Chst3), respectively, are prerequisites for the synthesis 
of the disulfated CS/DS-D and CS/DS-E units. The sulfotransferases responsible for this 
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activity are uronyl 2-O-sulfotransferase (Ust) and GalNAc 4S-6-O-sulfotransferase 
(Chst15) for the biosynthesis of CS/DS-D and CS/DS-E, respectively.11,28  
    KS biosynthesis, unlike the other family of GAGs, begins with the appendage of 
an oligosaccharide core that depends on if it is N-linked (KS I) or O-linked (KS II). KS I 
shares the same core oligosaccharide as all human N-linked glycans, a Man-GlcNAc-
GlcNAc trisaccharide that is core fucosylated on the reducing end GlcNAc. The nonreducing 
end mannose (Man) is further elaborated into a biantennary structure with two Man units. 
One branch is further elaborated into KS, while the other becomes a shorter oligosaccharide 
terminated with sialic acid. The KS II core oligosaccharide contains a singular GalNAc 
residue appended to serine or threonine sidechains that branches into GlcNAc and Gal. The 
KS linear polysaccharide is attached to the GlcNAc branch, while the Gal-containing antenna 
is usually terminated immediately by sialic acid. KS disaccharide units are polymerized by a 
collection of N-acetylglucosaminyltransferases (GlcNAcT-I, -II, and -VII) and 
galactosyltransferases (GalT-I-IV). Sulfation can then occur on the 6-O hydroxyl groups of 
both GlcNAc and Gal residues. GlcNAc sulfation is carried through by GlcNAc 6-O-
sulfotransferases (Chst2, Chst4, Chst6), while Gal sulfation is catalyzed by the Gal 6-O-
sulfotransferase (Chst1).10,29       
 
Glycosaminoglycan Sulfotransferases 
As indicated before, the sulfation patterns of GAGs are tightly regulated by a large 
family of sulfotransferase enzymes. Two major classes of sulfotransferases, cytosolic and  
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Figure 1.3. Illustrative representation of CS biosynthesis. Xyl, xylose; XylT, 
xylosyltransferase; Gal, galactose; GalT, galactosyltransferase; GlcA, glucuronic acid; 
GlcAT, glucuronyltransferase; GalNAc, N-acetylgalactosamine; GalNAcT, N-
acetylgalactosaminyltransferase; ChSy, chondroitin synthetase; Chst11, CS 4-O-
sulfotransferase; Chst3, CS 6-O-sulfotransferase; Chst15, GalNAc 4S-6-O-
sulfotransferase; Ust, uronylsulfotransferase; PAPS, 3’-phosphoadenosine-5’-
phosphosulfate. 
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membrane-associated, catalyze the transfer of a sulfuryl group from the donor molecule 
3’-phosphoadenosine-5’-phosphosulfate (PAPS) to a variety of amine- and hydroxyl-
containing substrates. Cytosolic sulfotransferases sulfonate small molecules, such as 
hormones, bioamines, drugs, and other xenobiotic agents. Membrane-associated 
sulfotransferases sulfonate larger biomolecules, including proteins and GAGs.30    
Specifically, GAG sulfotransferases are Golgi-membrane resident enzymes capable 
of sulfonating free hydroxyl or amine groups on the polymerizing GAG polysaccharide 
chain. Their overall structure comprises of a single pass transmembrane domain (with the 
exception of Hs3st), stem region, and luminal catalytic domain.31 The majority of known 
sulfotransferase crystal structures are of the cytosolic class. The limited information about 
GAG sulfotransferase structure has contributed to the difficulty of developing tools to study 
them. Genetic manipulation of these sulfotransferases have implicated them in many cellular 
functions, including cell migration,32 cancer metastasis,33 and development.34,35 Thus, 
therapies and tools to interrogate GAG sulfation have the potential to be extremely useful. 
Even though there are large differences between the acceptor substrates of the 
sulfotransferase family, they all have a sequence and structurally conserved PAPS-binding 
site. The structural features important for PAPS binding comprise of a 5’-phosphosulfate-
binding (PSB) loop, 3’-phosphate-binding (PB) loop, and a β-strand-loop-α-helix (SLH3) 
motif that interacts with the adenosine ring.36 Key amino acids often include hydrogen bond 
promoting and basic residues to counter balance negative charge. Due to the conserved nature 
of this domain and the similarity between PAPS and adenosine triphosphate (ATP), the 
phosphate donor of kinases, kinase inhibitor library scaffolds have been used as starting 
points for drug discovery against these enzymes.37,38 
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Based on the structural similarities and utilization of the sulfuryl donor, PAPS, it 
is hypothesized that sulfotransferases share a common catalytic mechanism.39 The 
mechanism that has been proposed for cytosolic sulfotransferases proceeds through an SN2-
like reaction whereby the acceptor hydroxyl acts as a nucleophile and attacks the sulfur atom 
of PAPS. This mechanism hinges on conserved basic residues to serve as a catalytic base and 
stabilize negative charge buildup on the leaving 3’-phosphoadenosine-5’-phosphate (PAP) 
group.30 These residues are typically conserved histidine and lysine residues in cytosolic 
sulfotransferases. However, in Ndst and Hs3st, the catalytic histidine has been suggested to 
be replaced by a glutamate.40 In order to rationally design chemical tools to study this family 
of enzymes, we will need to further understand their structure and mechanism.  
 
Biological Role of Sulfation on Glycosaminoglycans 
The importance of GAG sulfation has been known for decades. However, the 
complexities of the molecule have limited the ways it can be studied to genetic manipulations 
and challenging chemical syntheses. Nevertheless, some studies that have been reported have 
shown striking biological implications, including anti-coagulation, viral invasion, macular 
dystrophy, and spinal cord injury.  
The sulfation of heparin and HS are critical in the biological contexts of anti-
coagulation and viral invasion. The anti-coagulant drug activity of heparin is the result of the 
interaction between a specifically sulfated pentasaccharide sequence and antithrombin III. 
Removal of specific sulfate groups within this pentasaccharide abolishes its anti-coagulant 
activity.41 In another biological context, expression cloning experiments in cells resistant to 
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herpes simplex virus (HSV) invasion were used to show how HS 3-O sulfation was 
necessary for viral invasion.1 
Macular corneal dystrophy (MCD) is an autosomal recessive hereditary disease that 
results in a loss of vision and eventually necessitates a corneal transplant. It was discovered 
that patients with MCD have mutations and large genomic deletions/replacements in or 
before the encoding of Chst6, the sulfotransferase responsible for 6-O sulfation of GlcNAc 
residues in keratan sulfate. These changes were determined to be causative for the disease.42   
A transgenic mouse overexpressing the human 6-O-sulfotransferase (Chst3) revealed 
the effects of sulfation on cortical plasticity. The ratio of the two most abundant sulfation 
motifs, CS-A and CS-C, play a large role in determining the end of a critical period in ocular 
development. Transgenic mice with an increase in 6-O sulfation retained ocular dominance 
plasticity at a time that usually coincides with the end of the critical period of cortical 
plasticity. The decrease in sulfation prevented the accumulation of CS around neuronal 
synapses and localization of Otx2 homeoprotein, a regulator of interneuronal maturation.21     
Our lab’s long-standing interest in CS and its roles in neuroregeneration were inspired 
by its known inhibitory role in spinal cord injury. Studies have shown that digestion of CS 
at the site of injury with chondroitinase ABC (ChABC) leads to axon regeneration and 
functional recovery.8,43-45 We discovered that a specific sulfation motif, CS-E, was primarily 
responsible for the inhibitory effects of CS, and we determined that a monoclonal antibody 
against CS-E was capable of promoting optic nerve regeneration in vivo.46 These studies 
suggested that blocking the CS-E motif might be an exciting, new strategy for neuronal 
repair. 
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Tools for Modulating Glycosaminoglycan Sulfation 
While there are many tools to study the general role of GAGs in biological contexts 
(samples purified from natural sources, genetic models, antibodies, enzymes, small 
molecules), the methods to specifically modulate and study sulfation is far more limited. 
Cellular sulfation levels are typically manipulated genetically or by using sodium chlorate. 
Genetically altering the expression of the sulfotransferases that regulate sulfation is 
a common technique to study GAG sulfation. It can allow for the manipulation of a particular 
sulfation motif, such as the example of the CS 6-O sulfotransferase discussed above. 
However, there are drawbacks of genetic knockdown and knockout models. Unknown 
effects of compensatory mechanisms can play a significant role in displayed phenotypes. 
There are many sulfotransferases with redundant activity in the GAG biosynthetic pathway 
which can play a role in limiting the usefulness of information from these models. 
Additionally, from a therapeutic perspective, methods to manipulate gene expression are still 
not yet viable.    
Alternatively, small molecules benefit from their ease of use and potential for 
therapeutic development. Sodium chlorate is a simple molecule that inhibits the adenosine 
triphosphate (ATP) sulfurylase activity of PAPS synthetase, the enzyme that produces PAPS. 
Crystallographic data has previously suggested that inhibition occurs in a noncompetitive 
fashion by the blocking of the release of the pyrophosphate and adenosine 5’-phosphosulfate 
(APS) products from the enzyme active site.47 Inhibition of ATP sulfurylase activity globally 
affects all types of sulfation and thus has a multitude of potential off-target effects beyond 
GAG sulfation. It is typically used at high in vitro working concentrations in the range of 10 
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to 50 mM.  Furthermore, along with its millimolar effective concentration, its oxidative 
potential and toxicity preclude it from being used therapeutically.48,49 The ability to 
selectively target GAG sulfotransferases with small molecules would provide a valuable set 
of new chemical genetic tools for manipulating and understanding GAGs. 
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C h a p t e r  2  
CHST15-ANTAGONIST HIGH-THROUGHPUT SCREEN AND 
VALIDATION 
Introduction 
The ability to selectively target GAG sulfotransferases with small molecules would 
provide a valuable set of new chemical genetic tools for manipulating and understanding 
GAGs. Such molecules will also be essential for controlling GAG-mediated processes 
involved in various diseases. Notably, GAG sulfation patterns play an important role in the 
progression and treatment of diseases such as spinal cord injury,1-3 Alzheimer’s disease,4 
osteoarthritis,5,6 cancer,7,8 malaria,9,10 herpes,11 and macular dystrophy.12,13 One approach to 
discover novel scaffolds that can inhibit these enzymes is through high-throughput screening. 
Here, we developed and optimized a fluorescent high-throughput screen to identify small 
molecule inhibitors against Chst15. The assay was miniaturized and screened against a 
70,000 compound library. Hit compounds were validated by secondary radioisotope labeling 
assays for further lead development. 
 
Results and Discussion 
To begin to identify small molecules that could inhibit Chst15 activity, we opted to 
develop a fluorescent, enzyme coupled screen. This screen was based around a previously 
reported assay utilizing a PAPS regeneration cycle (Figure 2.1).14,15 In this assay, the 
coupled enzyme, aryl sulfotransferase IV (Sult1c1), has the ability to convert PAP to PAPS 
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by using 4-methylumbelliferyl sulfate (MUS) as the sulfate donor. Fluorescent 4-
methylumbelliferone (MU) is generated by the liberation of this sulfate moiety from MUS. 
In this way, since Chst15 utilizes PAPS to generate CS-E, disruption of this PAPS 
regeneration cycle would allow us to effectively monitor inhibition levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CS-A 
PAPS 
CS-E 
PAP 
MUS MU 
Chst15 
Sult1a1 
Figure 2.1. High-throughput assay for the discovery of Chst15 small molecule inhibitors. 
Inhibition of Chst15 was monitored through a fluorescent, enzyme-coupled readout. 
Fluorescence was generated by the conversion of MUS to MU by Sult1c1, which is linked 
to Chst15 via a PAPS regeneration cycle.  
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To develop such as assay, we began by bacterially expressing a maltose binding 
protein (MBP) fusion of the luminal catalytic domain of Chst15. After affinity purification, 
we recognized that the protein was co-purified with the chaperone proteins and possible 
truncations. We ensured that sulfotransferase activity was the result of the intended 
construct by designing and expressing K263A, R393A, and S400A mutants of Chst15. 
These designed mutations were all within the conserved PAPS binding domain. As 
expected, the mutations greatly attenuated activity when tested by a radioisotope labeling 
assay, indicating that the sulfotransferase activity witnessed from the wild type (WT) 
construct was the source of sulfotransferase activity (Figure 2.2). 
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Figure 2.2. (A) Radioactive isotope 
labeling assay for the direct 
detection of GAG sulfotransferase 
activity. (B) Chst15 expression 
constructs bearing mutations to key 
residues in the PAPS binding site 
greatly attenuate sulfotransferase 
activity. 
A 
B 
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With an active enzyme in hand, we sought to test and optimize the fluorescent assay 
in a 96-well plate format. Two parameters that are critical for a high quality assay are a 
large signal-to-noise ratio (SNR) and a Z-factor (Z’) greater than 0.5. We posited that the 
factors that would be most important for maximizing these parameters were pre-incubation 
time and enzyme concentrations. When Sult1c1 is bacterially expressed, it is known to co-
purify with PAP tightly bound in the active site.16,17 Any PAP impurities at the start of the 
assay reaction would lead to immediate generation of fluorescent signal that is not a result 
of Chst15 activity. Therefore, it was essential to pre-incubate Sult1c1 with the other 
components of the assay minus Chst15 and allow full conversion of PAP impurities to 
PAPS. This starting background signal can then be subtracted from the overall increase 
after the addition of Chst15. We determined that after a 1 h pre-incubation time, the 
increase in background signal as a result of PAP impurities had begun to plateau and would 
negligibly affect the signal to noise ratio (Figure 2.3A).   
The next assay components that were optimized were Sult1c1 and Chst15 enzyme 
concentrations. A high concentration of Sult1c1 was necessary for the immediate 
conversion of PAP to PAPS. This way, the rate limiting factor in the assay would be Chst15 
activity and thus, maximize the SNR ratio. In the end, we were able to increase Sult1c1 
concentrations to 0.1 µg/µL, which limited by protein stability and final glycerol 
concentrations (Figure 2.3B). Next, when Chst15 concentration was varied, we noticed a 
strong increase in fluorescent signal with a higher concentrations, similar to the effects of 
Sult1c1. From this data, we believed that the SNR and Z’ could be tuned after 
miniaturization by varying the enzyme concentration (Figure 2.3C). The SNR and Z’ at a 
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Chst15 concentration of 0.5 µg/µL was 6.14 and 0.62, respectively, after 15 min, well 
within the optimal assay range. 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
Another important factor that plays key role in the quality of hits gained from the 
screen includes the concentration of the enzyme substrates. Assaying at the Km of both 
Figure 2.3. (A) Fluorimetry revealed an optimal pre-incubation time of 1 h to remove 
background fluorescence caused by PAP impurities. (B) Increasing Sult1c1 concentration, 
to a maximal of 0.1 µg/µL, led to robust conversion of PAP to PAPS. (C) Increasing the 
concentration of Chst15 also led to greater fluorescence. Larger amounts of Chst15 could 
be used to increase the assay SNR and Z’.  
A B 
C 
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substrates enables the best coverage of both competitive and uncompetitive inhibitors.18  
We used fluorimetry to monitor initial reaction rates at varying substrate concentrations 
under pseudo-first order conditions. The Km’s for CS-A and PAPS were determined to be 
1.11 mM and 32.91 µM, respectively (Figure 2.4).  
 
 
 
 
 
 
 
 
With an optimized assay in hand, in collaboration with the Genomics Institute of 
the Novartis Research Foundation (GNF), we were able to miniaturize the assay to a 1536-
well plate format. For the high-throughput assay, Chst15 was expressed in HEK293F cells 
as it was more feasible to generate enough active enzyme necessary to run the screen. The 
Z’ for the miniaturized assay was 0.5, sufficient for screening. A diversity set of 70,000 
small molecules were screened at 12.5 µM to determine if they could decrease the 
detectable levels of fluorescence. We additionally counterscreened any small molecule that 
decreased the fluorescence of the complete, enzyme-coupled assay against Sult1c1 alone 
A B 
Figure 2.4. The Km of PAPS and CS-A were determined to be 32.91 µM and 1.11 mM, 
respectively, for Chst15 under optimized assay conditions.  
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to eliminate nonspecific inhibitors. After both initial screens, 26 compounds emerged to 
inhibit Chst15 with low Sult1c1 inhibition.  
 
 
 
 
 
 
 
 
 
 
 
 
Further validation of the hits were performed by reassessing in a 96-well plate 
format as well as the same direct, sensitive radioactive assay used previously (Figure 2.2A). 
First, 19 of the 26 hits (Figure 2.5) were obtained commercially and retested in the 
counterscreen in a 96-well plate format. It was determined that 12 of the 22 hits actually 
inhibited Sult1c1 (Figure 2.6A). The 7 hits that did not were carried through to the full 
Figure 2.5. Structures of 19 of the 26 small-molecule hits that were commercially 
available for further evaluation.   
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fluorescence assay. 5 of the 7 hits showed appreciable inhibitory activity specific for 
Chst15 at 12.5 µM (Figure 2.6B).  
However, drawbacks to the fluorescence assay include the complications that may 
arise from a system of indirect measurement of Chst15 activity and that the method 
eliminates potential lead scaffolds that may inhibit both Chst15 and Sult1c1. Therefore, to 
eliminate these complications, we opted to also test the hit compounds in the radioactive 
isotope labeling assay. 2 of the 19 hits showed inhibitory activity at high concentrations of 
100 µM when analyzed in this format (Figure 2.7A). The inhibitory activity of these small 
molecules, 5 and 19, were further confirmed through dose response experiments. The IC50 
of compounds 5 and 19 were determined to be 23 µM and 39 µM, respectively (Figure 
2.7B).  We surmised that this assay was more indicative of a working Chst15 inhibitor 
because it was a direct measurement of activity. Therefore, these two lead scaffolds were 
moved on for further development.         
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A B 
Figure 2.6. 19 of 26 available compounds were obtained and retested for Sult1c1 
inhibition via the fluorescence assay. (A) 7 of 19 compounds did not appreciably inhibit 
the Sult1c1 at 12.5 µM. (B) The 7 compounds that did not inhibit Sult1c1 were retested 
in the full fluorescence assay. 5 of 7 compounds inhibited Chst15 at 12.5 µM. Values 
shown are the mean ± S.E.M. (n = 3). 
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Conclusion 
In conclusion, here we designed and optimized a fluorescent, enzyme-coupled 
high-throughput screen for small molecule inhibitors against Chst15. Using this assay, we 
screened 70,000 molecules in collaboration with GNF. Of the 26 putative hits, 2 hits, 
compounds 5 and 10, were confirmed to have dose dependent, micromolar potency against 
the enzyme in vitro. It will be important to further optimize and characterize these scaffolds 
to generate inhibitors with an inhibitory activity, specificity, and pharmacokinetic profile 
favorable for in vivo studies. This fluorescent screen should also be amenable for the 
evaluation of all cytosolic and membrane-bound sulfotransferases. Therefore, it could be 
designed for the discovery of small-molecule modulators of other GAG sulfotransferases 
to potentially attain a suite of inhibitors specific for different sulfation motifs.   
A B 
Figure 2.7. Validation of candidate compounds identified in the ~70,000 compound 
primary screen leads to two scaffolds. (A) 19 of 26 lead compounds were obtained and 
tested directly against Chst15 in a radioisotope labeling assay at 100 µM to confirm the 
inhibitory activity of two compounds, 5 and 19.  (B) Dose dependent inhibition was seen 
with compounds 5 (IC50 = 23 µM) and 19 (IC50 = 39 µM). All values reported as the mean 
of duplicate experiments. 
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Experimental Methods 
Expression and Purification of Chst15. Origami B(DE3) (Novagen) harboring the pGro7 
(TaKaRa) and pMAL-c2X-mChst15151-561 constructs were kindly provided by Dr. Jian Liu 
(UNC-Chapel Hill). Cells were grown in LB medium (1L) at 37°C. When cells reached an 
OD600 of 0.8, cells were moved to 22°C for 30 minutes. Isopropyl β-D-1-
thiogalactopyranoside (IPTG) and L-(+)-arabinose was added to the cells at the final 
concentrations of 0.2 mM and 1 mg/mL, respectively, after the 30 minutes and cells were 
incubated for an additional 18 hours at 22°C. The pelleted cells were lysed in a cold buffer 
containing 20 mM Tris pH 7.5, 500 mM NaCl, 1 mM EDTA, and 1x CompleteTM protease 
inhibitors (Roche) by sonication. After centrifugation, the clarified lysate was added to pre-
equilibrated amylose resin beads (New England Biolabs) and incubated at 4°C for 1 hour 
with end-over-end rotation. The beads were then washed 4 times with a buffer containing 
20 mM Tris pH 7.5, 500 mM NaCl, and 1 mM EDTA and eluted with a buffer containing 
20 mM Tris pH 7.5, 500 mM NaCl, 1 mM EDTA, and 10 mM D-(+)-maltose. After SDS-
PAGE analysis, the purified protein was concentrated with a 50 kDa molecular weight cut-
off (MWCO) spin filter (Millipore), buffer exchanged into 20 mM Tris pH 7.5, 500 mM 
NaCl, and 1 mM EDTA, and 50% glycerol, and stored at -20°C. 
 
Expression and Purification of Sult1c1. BL21(DE3)RIL (Stratagene) harboring the 
pET28a-Sult1c1 was kindly provided by Dr. Jian Liu (UNC-Chapel Hill). Cells were 
grown in LB medium (1L) at 37°C. When cells reached an OD600 of 0.8, cells were moved 
to 22°C for 30 minutes. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the 
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cells at the final concentrations of 0.2 mM after the 30 minutes and cells were incubated 
for an additional 18 hours at 22°C. The pelleted cells were lysed in a cold buffer containing 
25 mM Tris pH 7.5, 500 mM NaCl, 10 mM imidazole, and 1x EDTA-free CompleteTM 
protease inhibitors (Roche) by sonication. After centrifugation, the clarified lysate was 
added to pre-equilibrated Ni-NTA resin beads (Qiagen) and incubated at 4°C for 1 hour 
with end-over-end rotation. The beads were then washed 3 times with a buffer containing 
25 mM Tris pH 7.5, 500 mM NaCl, and 10 mM imidazole, washed 1 time with 25 mM 
Tris pH 7.5, 500 mM NaCl, and 50 mM imidazole and eluted with a buffer containing 25 
mM Tris pH 7.5, 500 mM NaCl, and 250 mM imidazole. After SDS-PAGE analysis, the 
purified protein was concentrated with a 30,000 Da molecular weight cut-off (MWCO) 
spin filter (Millipore), buffer exchanged into 25 mM Tris pH 7.5, 500 mM NaCl, and 50% 
glycerol, and stored at -20°C. 
 
Enzymatic Synthesis and Purification of PAPS and 35S-PAPS. Adenosine 
5’triphosphate (ATP, 11.8 mM), MgCl2 (11.8 mM), phosphoenolpyruvic acid (PEP, 24 
mM), and NaSO4 (118 mM) were dissolved into 137 µL of 50 mM Tris pH 8.0. If 35S-
PAPS is to be synthesized, 25 µL of 35S-NaSO4 (10 mCi/mL stock, American Radiolabeled 
Chemicals Inc.) was added to the reaction. If not, 25 µL of water was added instead. After, 
1 µL each of pyruvate kinase (700 units/mL, Sigma), inorganic pyrophosphatase (250 
units/mL, Sigma), ATP sulfurylase (2 units/mL, Sigma), and APS kinase (5 mg/mL, 
generously donated from Dr. Andrew Fisher (UC-Davis)) were added to the reaction 
mixture. The reaction was allowed to incubate at 37°C for 9 hours. After 9 hours, an 
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additional 1 µL of the same four enzymes were added and the reaction was allowed to 
proceed an additional 12 hours at 37°C. Purification of PAPS was achieved using DEAE-
cellulose (Whatman) column (2.5 mL resin) pre-equilibrated with water and eluted using a 
gradient of 0-500 mM NaCl. Fractions were lyophilized, reconstituted in 170 µL of 1 mM 
Tris pH 8.0, and analyzed with HPLC using a Zorbax-NH2 column (4.6 mm x 150 mm, 
Agilent). The following method was applied: 100% water for 10 minutes, followed by a 
linear gradient of 0-100% 1 M KH2PO4 for 30 minutes, followed by 100% 1 M KH2PO4 
for 15 minutes at a flow rate of 1 mL/min with UV 254 nM detection. Fractions containing 
PAPS were stored at -80°C. 
96-Well Plate Enzyme-Coupled, Fluorescent Assay. For full assay, the substrates PAPS 
and CS-A (Sigma) were added to a solution containing 100 mM Tris pH 7.6, 1 mM β-
mercaptoethanol, and 5 mM 4-methylumbelliferyl sulfate at a concentration of 30 µM and 
1 mM, respectively, to a total volume of 74 µL. 5 µL of Sult1c1 (2 mg/mL) was added to 
the mixture and incubated at 37°C for 1 hour. 20 µL of Chst15 (1 mg/mL), pre-incubated 
with 1 µL of DMSO or inhibitor stock for 30 minutes, was then added to the mixture to 
initiate the reaction. The 96-well plate was read using either a Victor3 Plate Reader (Perkin 
Elmer) or Flexstation 3 (Molecular Devices) at excitation and emission wavelengths of 360 
nm and 449 nm respectively.  
 For the counter screen, the substrates PAPS and CS-A (Sigma) were also added to 
a solution containing 100 mM Tris pH 7.6, 1 mM β-mercaptoethanol, and 5 mM 4-
methylumbelliferyl sulfate at a concentration of 30 µM and 1 mM, respectively, to a total 
volume of 75 µL. The reaction was initiated by adding a mixture of 5 µL of Sult1c1, 19 
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µL of 100 mM Tris pH 7.6, and 1 µL of DMSO or inhibitor stock that has been pre-
incubated at room temperature for 30 minutes.   
 
1536-Well Plate High-Throughput Screening Protocol. For the full assay, 2 µL of 
Chst15 (0.46 mg/mL) was added to each well in black 1526-well plates pre-plated with the 
small molecule library (12.5 µM final concentration). The mixture was incubated for 5 
minutes with shaking. Then, 2 µL of a mixture containing 100 mM Tris pH 7.6, 1 mM β-
mercaptoethanol, 5 mM 4-methylumbelliferyl sulfate, 1 mM CS-A, 30 µM PAPS, and 0.1 
mg/mL Sult1a1 was added to the plate and read as the 0 minute time point on a PheraStar 
Plate Reader with an excitation wavelength of 350 nm and emission wavelength of 460 
nm. The plate was incubated at 37°C for 30 minutes and was read again at the same 
wavelengths. For the counter screen, Chst15 was omitted. 
 
Chst15 Radioisotope Labeling Assay. Chst15 activity was determined by incubating 
Chst15 with 150 µg of CS-A (Sigma) and 30 µM 35S-PAPS in 150 µL of reaction buffer 
(100 mM Tris pH 7.6, 5 mM β-mercaptoethanol) for 30 minutes at 37°C. For assaying the 
potency of inhibitors, 1.25 µL of a DMSO stock was pre-incubated with Chst15 alone for 
1 hour at room temperature prior to the addition of the substrates in reaction buffer. The 
samples were then subjected to DEAE-Sepharose chromatography (200 µL slurry per 
reaction) to purify the 35S-labeled product. Samples were washed 3 times with 1 mL of a 
buffer containing 50 mM NaOAc pH 5.5, 150 mM NaCl, 6 M urea, 1 mM EDTA, and 
0.01% Triton X-100, washed 2 times with 1 mL of a buffer containing 50 mM NaOAc pH 
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5.5, 250 mM NaCl, and 0.01% Triton X-100, and eluted with 1 mL of a buffer containing 
50 mM NaOAc pH 5.5, 1 M NaCl, and 0.01% Triton X-100. The elution was mixed with 
7 mL of Ecoscint XR scintillation fluid (National Diagnostics) and activity was quantified 
with a liquid scintillation counter (Beckman LS6500). 
 
Assay Optimization with Fluorimetry. The substrates PAPS and CS-A (Sigma) were 
added to a solution containing 100 mM Tris pH 7.6, 1 mM β-mercaptoethanol, and 5 mM 
4-methylumbelliferyl sulfate at a concentration of 30 µM and 1 mM, respectively, to a total 
volume of 75 µL. 5 µL of Sult1a1 (2 mg/mL) was added to the mixture and incubated at 
37°C for 1 hour. 20 µL of Chst15 (1 mg/mL) was then added to the mixture to initiate the 
reaction. The reaction mixture was added to a sub-micro fluorimeter cell (Starna Cells) and 
product formation was monitored for 10 minutes at excitation and emission wavelengths 
of 360 nm and 449 nm respectively using a steady-state fluorimeter (Caltech BILRC). Km 
of the substrates was determined by varying substrate PAPS (10 µM to 200 µM) or CS-A 
(0.5 mM to 10 mM) concentrations and nonlinear regression analysis of initial velocity vs 
substrate concentration using Kaleidagraph (version 4.1.2).  
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C h a p t e r  3  
STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS OF LEAD 
SCAFFOLDS 
Introduction 
The high-throughput screen we previously developed revealed two lead scaffolds, 
5 and 19, as millimolar inhibitors of Chst15. Traditionally, to learn about the implications 
of the structural components of each scaffold, libraries of compound analogs are often 
assembled. Decades of medicinal chemistry research have taught us that these chemical 
changes, most often composed of subtle, isoteric variations, but may also consist of large 
molecular additions, can help elucidate the key moieties important for inhibitor potency.1-
3 Here, we obtained commercially available and chemically synthesized analogs of lead 
compounds 5 and 19. Using a radioactive isotope labeling assay, we evaluated the 
structure-activity relationship of the changes as compared to the original hit compounds. 
We determined that compound 19 would be the most promising scaffold to further develop 
based on specificity and chemical tractability of the hit molecules. Fine tuning of the 
substituents on the anilide moiety of 19 led to a 3-fold improvement. This optimized 
compound will be carried through for further cellular and potentially in vivo analysis.   
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Results and Discussion 
To assess the structure-activity relationship of these two molecules, we obtained 
commercially available and chemically synthesized analogs based around the two 
pharmacophores. Several different analogs of 5 were obtained commercially and tested 
with the radioisotope labeling assay; however, none of the changes improved the inhibition 
relative to the original compound when tested at 20 µM (Figure 3.1). Interestingly, 5 is a 
known c-Raf inhibitor and when retested in the counter screen, inhibited Sult1c1 as well 
(Figure 2.6A).4 Due to these potential off-target effects, we decided to focus our attention 
on 19.  
Thirty-one analogs of 19 were synthesized chemically or obtained from commercial 
sources. To generate the analogs, we used two different synthetic routes depending on the 
molecule’s diversification point of interest. Synthesis of the α,β-unsaturated acid first gave 
us access to changing the functional groups around the anilide by N,N’-
diisopropylcarbodiimide (DIC) promoted amide bond coupling (Scheme 3.1). Synthesis of 
the cyanoacetamide in two steps allowed us to append different aryl-aldehyde 
intermediates by piperidinium acetate-catalyzed Knoevenagel condensation (Scheme 3.2).5 
Compounds were purified by column chromatography and if necessary by HPLC 
purification. 
Using the same radioisotope labeling assay as before, we were able to compare the 
relative inhibitory activity of each small molecule (Table 3.1, Table 3.2, and Figure 3.2). 
First, we individually removed the aromatic rings on each end of the molecule and, as 
expected, abolished bioactivity (21, 22, 25), indicative of their importance in the 
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pharmacophore. We then sought to change the substituents on the anilide functional group. 
We reasoned that changing the substituents at the position “para” to the rest of the molecule 
would likely extend it most and potentially change steric interactions if located in a binding 
cleft. However, our findings indicated that removing the di-substitution on the anilide ring 
greatly decreased the relative inhibitory activity as was seen with all analogs containing 
only a mono-substituted ring (28-36). Altering the position of the mono-substitution (34, 
35) also did not change this trend. Even large substitutions, such as tert-butyl (33) and 
phenyl groups (36, 50), were not able to compensate for the loss in activity. This was 
especially evident in the di-chloro analogs (37-39), as they all had comparable, if not 
greater, potency to the original lead compound 19. 
 
  
    
Figure 3.1. Comparison of chemical analogs to lead compound 5. Relative inhibition values 
are given for each compound as compared to the original hit 5. Compounds were assessed 
through the radiolabeling assay at 20 µM. Mean values of duplicate experiments are 
reported.  
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aReagents and conditions: (a) cyanoacetic acid, DIC, THF (45%); (b) piperidine AcOH, 
PhMe (52-93%). 
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aReagents and conditions: (a) ethyl cyanoacetate, piperidine, AcOH, PhMe (91%); (b) 
NaOH, THF (77%); (c) DIC, THF (17-56%).  
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Removal of any of the substituents on the vinylbenzene ring (40, 44, 47) greatly 
attenuated the inhibitory potency of the compound indicating the importance each has in 
the bioactivity of the molecule. Replacement of the original bromo substituent with 
different halogens showed that the steric interactions elicited by the bromo group was ideal 
for the binding pocket (41-43). While the larger iodo substituent was tolerated, there was 
a slight decline in activity (43). Smaller halogens were not as well tolerated and led to a 2-
2.5-fold loss in inhibitory activity (41, 42) as compared to the original lead compound. 
Slight modification to bromo (45) or extension to ethoxy (46) of the original 
methoxy group produced compounds with inhibitory activities comparable to or better than 
that of the original lead scaffold. However, when comparing to the most active, similar 
scaffold, 37, only the ethoxy group change is well tolerated by retaining 93% of its 
inhibitory activity. Extension at this position could potentially be used for further 
elaboration in the future.  
Meanwhile, amino and indazole isosteres of the phenol group (48, 51) were not 
well tolerated, with a drop in potency of 3-fold and 26-fold respectively. Methylation of 
the phenol functionality also drastically lowered inhibitory potency when comparing 
compounds with common scaffolds (38, 49). It is likely that the electronic and hydrogen 
bonding properties of the phenol group are necessary for the bioactivity of the inhibitor. 
Interestingly, reduction of the acrylamide double bond led to a 9-fold reduction in 
potency and loss of dose dependent inhibitory activity (52). Mechanistically, this alkene 
could potentially serve as an electrophilic site for a nucleophilic amino acid sidechain 
and/or increase the rigidity of the molecule by restricting the rotational freedom of the 
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bond. Rotating frame nuclear Overhauser effect spectroscopy (ROESY) data suggested 
that the E-isomer is generated from the Knoevengel condensation (Experimental Methods). 
Coupling between the amide and alkene protons was detected in 37 and is only possible in 
the E-configuration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1. Chst15 Inhibition Relative to 19 of 
Anilide-Analogs at 25 µM.  
Table 3.2. Chst15 Inhibition Relative to 19 of 
Vinylbenzene-Analogs at 25 µM.  
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Conclusion 
In conclusion, here we used commercially available and chemically synthesized 
analogs to evaluate the structure-activity relationships of the components of the lead 
scaffolds. Due to the known off target effects of compound 5, we decided to focus our 
attention on developing 19. A straightforward, 2-3 step synthetic route led to the facile 
assembly of 19 analogs. Comparative analysis revealed many structural components that 
were critical for inhibitory activity, including the acrylamide olefin and the vinylbenzene 
phenol.  Subtle changes to the substituents around the anliide ring were able to potentiate 
a 3-fold increase in potency and this compound, 37, will be characterized further. For future 
Figure 3.2. Comparison of additional chemical analogs to lead compound 19. Relative 
inhibition values are given for each compound as compared to the original hit 19. 
Compounds were assessed through the radiolabeling assay at 25 µM. The mean ± S.E.M. 
of triplicate experiments is reported.  
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studies, to accelerate the generation of more potent and potentially specific inhibitors, it 
would be ideal to gain structural information about how the molecule interacts with the 
target enzyme, Chst15. This would greatly narrow down the possible changes to the 
scaffold and facilitate rational design of the inhibitor.   
 
Experimental Methods 
General Methods. All reactions were carried out under an argon atmosphere unless 
otherwise specified. Reagents were purchased from Sigma Aldrich and used without 
purification unless otherwise specified. 1H NMR spectra were recorded with a Varian Inova 
500 (500 MHz) and are reported relative to residual solvent peaks. 13C NMR spectra were 
recorded with Varian Inova 500 (125 MHz) or Bruker AVANCE AV400 (100 MHz) and 
are reported relative to residual solvent peaks. ROESY NMR spectra were recorded with a 
Varian Inova 600 (600 MHz) spectrometer. Data for 1H NMR are reported as follows: 
chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration, assignment). 
Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, m = multiplet, br 
= broad. Data for 13C NMR are reported in terms of chemical shifts (δ ppm). High 
resolution mass spectra (HRMS) were acquired using an Agilent 6200 Series TOF with 
and Agilent G1978A Multimode source using mixed electrospray ionization/atmospheric 
pressure chemical ionization (MM: ESI-APCI). 
 
2-cyano-N-(2,4-dichlorophenyl)acetamide 
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Cyanoacetic acid (0.263 g, 3.09 mmol) was dissolved into 10 mL of THF at room 
temperature. A solution of 2,4-dichloroaniline (0.500, 3.09 mmol) in 5 mL of THF was 
added dropwise at room temperature.  After 5 minutes, a solution of DIC (0.478 mL, 3.09 
mmol) in 5mL of THF was added dropwise. The reaction was refluxed under argon for 1 
hr. The flask was then allowed to return to room temperature. The mixture was then filtered 
and the filtrate was concentrated in vacuo. The crude solid was then redissolved into EtOAc 
(20 mL) and the organic layer was extracted with 6 N HCl (20 mL x 3) and saturated 
NaHCO3 (20 mL x 3) successively. The organic layer was dried with MgSO4 and 
concentrated in vacuo. The solid was then recrystallized in DCM to afford a white solid 
(0.319 g, 45%). Rf 0.2 (8:2 Hex/EtOAc). 1H NMR (500 MHz, CD3OD) δ 8.25 (d, J = 8.9 
Hz, 1 H, ArH), 8.21 (br, 1 H, NH), 7.44 (d, J = 2.4 Hz, 1 H, ArH), 7.30 (dd, J = 2.4, 8.9 Hz, 
1 H, ArH), 3.62 (s, 2 H, CH2CN); 13C NMR (125 MHz, DMSO-d6) δ 159.23, 132.46, 
131.18, 129.47, 128.51, 124.68, 123.00, 114.20, 27.47. HRMS: [M-H]- calculated: 
226.9784, found: 226.9792. 
 
(E)-Ethyl 3-(3-bromo-4-hydroxy-5-methoxyphenyl)-2-cyanoacyrlate 
 
 
 
Ethyl cyanoacetate (1.12 mL, 10.5 mmol) and 5-bromovanillin (2,31 g, 10 mmol) was 
dissolved into 10 mL of toluene at room temperature. Piperidine (0.158 mL, 1.60 mmol) 
and glacial acetic acid (0.74 mL, 12.9 mmol) were then added to the previous mixture. The 
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mixture was refluxed for 3 hours. After 3 hours, the reaction was allowed to cool to room 
temperature. The precipitate was filtered, collected, and rinsed with ice cold methanol to 
yield a yellow solid (2.98 g, 91%). Rf 0.2 (1:1 Hex/EtOAc). 1H NMR (500 MHz, DMSO-
d6) δ 8.16 (s, 1 H, C=CH), 7.79 (s, 2 H, ArH), 4.35 (q, J = 7.1 Hz, 2 H, CH3CH2O), 3.94 
(s, 3 H, OCH3), 1.37 (t, J = 7.2 Hz, 3 H, CH3CH2O); 13C NMR (125 MHz, DMSO-d6) δ 
162.62, 154.03, 149.62, 148.64, 129.49, 123.90, 116.61, 113.56, 110.15, 99.54, 62.57, 
56.78, 14.47. HRMS: [M-H]- calculated: 323.9877, found: 323.9883. 
 
(E)-3-(3-bromo-4-hydroxy-5-methoxyphenyl)-2-cyanoacrylic acid 
 
 
 
Previously synthesized ethyl 3-(3-bromo-4-hydroxy-5-methoxyphenyl)-2-cyanoacyrlate 
(0.101 g, 0.311 mmol) was dissolved in 4 mL of THF. 2 N NaOH (10 mL) was added. The 
mixture was stirred at room temperature for 15 hours. After 15 hours, the reaction was 
neutralized with concentrated HCl. The reaction mixture was then extracted with EtOAc 
(3 x 10 mL). The organic layer was then washed with brine (10 mL), dried with MgSO4, 
and concentrated in vacuo. The resulting crude solid was then redissolved into 10:1 
DCM/EtOAc and purified by silica flash chromatography using 10:1 DCM/EtOAc and 
0.1% AcOH. A yellow solid was obtained after concentration in vacuo (0.071 g, 77%). Rf 
0.3 (9:1 DCM/MeOH). 1H NMR (500 MHz, DMSO-d6) δ 8.21 (s, 1 H, C=CH), 7.93 (s, 2 
H, ArH), 7.77 (s, 1 H, ArH), 3.88 (s, 3H, OCH3), 3.12 (s, 1 H, ArOH); 13C NMR (125 
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MHz, DMSO-d6) δ 165.43, 163.86, 151.12, 148.37, 128.51, 123.15, 117.65, 116.11, 
112.45, 109.96, 56.16. HRMS: [M-H]- calculated: 295.9564, found: 295.9578. 
 
General Procedure for Aldol Reaction: 
(E)-3-(3-bromo-4-hydroxy-5-methoxyphenyl)-2-cyano-N-(2,4-
dichlorophenyl)acrylamide 
 
 
 
Previously synthesized 2-cyano-N-(2,4-dichlorophenyl)acetamide (0.240 g, 1.05 mmol) 
and 5-bromovanillin (0.231 g, 1 mmol) was added to 5 mL of toluene. While stirring this 
mixture, piperidine (0.016 mL, 0.16 eq) and glacial acetic acid (0.074 mL, 1.25 eq) was 
added. The solution was stirred and heated to reflux for 3 hours. After 3 hours, the reaction 
was allowed to cool to room temperature. The precipitate was filtered, collected, and rinsed 
with ice cold methanol to yield a yellow solid (0.413 g, 93%). 1H NMR (500 MHz, DMSO-
d6) δ 10.88 (s, 1 H, ArOH), 10.01 (s, 1 H, NH), 8.22 (s, 1 H, C=CH), 7.90 (d, J = 2.0 Hz, 1 
H, ArH), 7.76 (d, J = 2.4 Hz, 1 H, ArH), 7.73 (d, J = 2.0 Hz, 1 H, ArH), 7.66 (d, J = 8.6 
Hz, 1 H, ArH), 7.49 (dd, J = 2.4, 8.6 Hz, 1 H, ArH), 3.89 (s, 3 H, OCH3); 13C NMR (125 
MHz, DMSO-d6) δ 160.58, 150.93, 148.62, 133.63, 131.00, 129.82, 129.15, 128.56, 
128.32, 127.83, 123.70, 116.73, 112.62, 109.34, 102.24, 56.33. HRMS: [M-H]- calculated: 
438.9257, found: 438.9258. 
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(E)-3-(3-chloro-4-hydroxy-5-methoxyphenyl)-2-cyano-N-(2,4-
dicholorophenyl)acrylamide 
 
 
 
3-Chloro-4-hydroxy-5-methoxybenzaldehyde (0.078 g, 0.417 mmol) was used in the same 
previous aldol reaction conditions (0.151 g, 91%).; 1H NMR (500 MHz, DMSO-d6) δ 10.83 
(s, 1 H, ArOH), 9.95 (s, 1 H, NH), 8.20 (s, 1 H, C=CH), 7.75 (d, J = 2.2 Hz, 2 H, ArH), 
7.68 (d, J = 8.6 Hz, 2 H, ArH), 7.49 (dd, J = 2.4, 8.6 Hz, 1 H, ArH), 3.88 (s, 3 H, OCH3);  
13C NMR (125 MHz, DMSO-d6) δ 161.00, 151.47, 149.09, 148.22, 134.08, 131.40, 130.18, 
129.57, 128.91, 128.26, 125.82, 123.29, 120.86, 117.18, 112.67, 102.73, 56.77. HRMS: 
[M-H]- calculated: 394.9762, found: 394.9780.  
 
(E)-2-cyano-N-(2,4-dichlorophenyl)-3-(3-fluoro-4-hydroxy-5-
methoxyphenyl)acrylamide 
 
 
 
3-fluoro-4-hydroxy-5-methoxybenzaldehyde (AstaTech Inc, 0.035 g, 0.208 mmol) was 
used in the same previous aldol reaction conditions (0.068 g, 86%).; 1H NMR (500 MHz, 
DMSO-d6) δ 9.94 (s, 1 H, NH), 8.20 (s, 1 H, C=CH), 7.74 (d, J = 2.4 Hz, 1 H, ArH), 7.68 
(d, J = 8.7 Hz, 1 H, ArH), 7.58 (m, 2 H, ArH) 7.48 (dd, J = 2.4, 8.7 Hz, 1 H, ArH), 3.86 (s, 
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3 H, OCH3);  13C NMR (125 MHz, DMSO-d6) δ 161.16, 152.56, 151.64, 150.66, 150.24, 
150.19, 134.18, 131.20, 129.89, 129.53, 128.60, 128.25, 117.49, 112.29, 112.13, 111.19, 
56.76. HRMS: [M-H]- calculated: 379.0058, found: 379.0074.  
 
(E)-2-cyano-N-(2,4-dichlorophenyl)-3-(4-hydroxy-3-iodo-5-
methoxyphenyl)acrylamide 
 
 
 
5-iodovanillin (0.058g, 0.208 mmol) was used in the same previous aldol reaction 
conditions (0.072 g, 71%).; 1H NMR (500 MHz, DMSO-d6) δ 10.87 (s, 1 H, NH), 9.90 (br, 
1 H, OH), 8.16 (s, 1 H, C=CH), 8.04 (s, 1 H, ArH), 7.74 (d, J = 2.4 Hz, 1 H, ArH), 7.72 (s, 
1 H, ArH), 7.68 (d, J = 8.7 Hz, 1 H, ArH), 7.48 (dd, J = 2.4, 8.6 Hz, 1 H, ArH), 3.86 (s, 3 
H, OCH3); 13C NMR (125 MHz, DMSO-d6) δ 160.54, 151.21, 150.53, 146.81, 134.42, 
133.56, 130.78, 129.52, 129.00, 127.69, 124.60, 116.67, 113.06, 101.77, 84.94, 56.11. 
HRMS: [M-H]- calculated: 486.9119, found: 486.9132. 
 
(E)-2-cyano-N-(2,4-dichlorophenyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide 
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Vanillin (0.032 g, 0.208 mmol) was used in the same previous aldol reaction conditions 
(0.067 g, 89%).;  1H NMR (500 MHz, DMSO-d6) δ 10.40 (s, 1 H, ArOH), 9.92 (s, 1 H, 
NH), 8.23 (s, 1 H, C=CH), 7.73 (m, 2 H, ArH), 7.67 (d, J = 8.6 Hz, 1 H, ArH), 7.57 (d, J = 
2.1, 8.4 Hz, 1 H, ArH) 7.48 (dd, J = 2.4, 8.7 Hz, 1 H, ArH), 6.98 (d, J = 8.3 Hz, 1 H, ArH), 
3.86 (s, 3 H, OCH3);  13C NMR (125 MHz, DMSO-d6) δ 160.78, 152.06, 152.00, 147.76, 
133.64, 130.67, 129.45, 128.96, 128.17, 127.66, 126.29, 123.00, 117.00, 115.99, 113.67, 
100.45, 55.58. HRMS: [M-H]- calculated: 361.0152, found: 361.0172. 
 
(E)-3-(3-bromo-4-hydroxyphenyl)-2-cyano-N-(2,4-dichlorophenyl)acrylamide 
 
 
 
3-Bromo-4-hydroxybenzaldehyde (0.042 g, 0.208 mmol) was used in the same previous 
aldol reaction conditions (0.044 g, 52%).; 1H NMR (500 MHz, DMSO-d6) δ 9.96 (s, 1 H, 
NH), 8.26 (d, J = 2.2 Hz, 1 H, ArH), 8.19 (s, 1 H, C=CH), 7.93 (dd, J = 2.3, 8.7 Hz, 1 H, 
ArH), 7.74 (d, J = 2.4 Hz, 1 H, ArH), 7.66 (d, J = 8.7 Hz, 1 H, ArH) 7.48 (dd, J = 2.4, 8.6 
Hz, 1 H, ArH), 7.10 (d, J = 8.6 Hz, 1 H, ArH);  13C NMR (125 MHz, DMSO-d6) δ 161.11, 
159.51, 159.48, 150.85, 136.11, 134.06, 132.45, 131.32, 130.14, 129.54, 128.90, 128.23, 
124.24, 117.40, 117.13, 110.86. HRMS: [M-H]- calculated: 408.9152, found: 408.9166. 
 
 (E)-2-cyano-3-(3,5-dibromo-4-hydroxyphenyl)-N-(2,4-dichlorophenyl)acrylamide 
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3,5-Dibromo-4-hydroxybenzaldehyde (0.058 g, 0.208 mmol) was used in the same 
previous aldol reaction conditions (0.084 g, 82%).; 1H NMR (500 MHz, DMSO-d6) δ 10.03 
(s, 1 H, NH), 8.27 (s, 2 H, ArH), 8.20 (s, 1 H, C=CH), 7.75 (d, J = 2.4 Hz, 1 H, ArH), 7.67 
(d, J = 8.7 Hz, 1 H, ArH), 7.49 (dd, J = 2.4, 8.6 Hz, 1 H, ArH); 13C NMR (125 MHz, 
DMSO-d6) δ 159.98, 154.88, 148.72, 134.22, 133.24, 130.69, 129.32, 128.83, 128.05, 
127.52, 125.08, 115.92, 111.84, 103.44. HRMS: [M-H]- calculated: 486.8257, found: 
486.8264. 
 
(E)-3-(3-bromo-5-ethoxy-4-hydroxyphenyl)-2-cyano-N-(2,4-
dichlorophenyl)acrylamide 
 
 
 
3-Bromo-5-ethoxy-4-hydroxybenzaldehyde (Alfa Aesar, 0.051 g, 0.208 mmol) was used 
in the same previous aldol reaction conditions (0.081 g, 85%).;  1H NMR (500 MHz, 
DMSO-d6) δ 10.62 (br s, 1 H, OH), 10.00 (s, 1 H, NH), 8.21 (s, 1 H, C=CH), 7.87 (d, J = 
1.7 Hz, 1 H, ArH), 7.75 (d, J = 2.3 Hz, 1 H, ArH), 7.72 (d, J = 1.7 Hz, 1 H, ArH), 7.65 (d, 
J = 8.7 Hz, 1 H, ArH), 7.49 (dd, J = 2.3, 8.6 Hz, 1 H, ArH); 13C NMR (125 MHz, DMSO-
d6) δ 160.93, 151.34, 149.26, 147.81, 134.00, 131.32, 129.86, 129.49, 128.80, 128.56, 
128.21, 124.25, 117.08, 113.84, 110.16, 102.89, 65.31, 14.79. HRMS: [M-H]- calculated: 
452.9414, found: 452.9429. 
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(E)-3-(3-bromo-5-methoxyphenyl)-2-cyano-N-(2,4-dichlorophenyl)acrylamide 
 
 
 
3-Bromo-5-methoxybenzaldehyde (AstaTech Inc., 0.100 g, 0.465 mmol) was used in the 
same previous aldol reaction conditions (0.138 g, 70%).;  1H NMR (500 MHz, DMSO-d6) 
δ 10.23 (s, 1 H, NH), 8.30 (s, 1 H, C=CH), 7.76 (d, J = 1.6 Hz, 1 H, ArH), 7.75 (d, J = 2.4 
Hz, 1 H, ArH), 7.63 (d, J = 8.6 Hz, 1 H, ArH), 7.58 (t, J = 1.7 Hz, 1 H, ArH), 7.49 (dd, J 
= 2.4, 8.6 Hz, 1 H, ArH), 7.43 (t, J = 1.6 Hz, 1 H, ArH), 3.84 (s, 3 H, OCH3); 13C NMR 
(126 MHz, DMSO-d6) δ 160.76, 160.45, 150.82, 134.99, 133.80, 131.72, 130.45, 129.66, 
129.22, 128.32, 125.07, 123.25, 121.03, 116.15, 115.42, 108.11, 56.39. HRMS: [M-H]- 
calculated: 422.9308, found: 422.9204. 
 
(E)-2-cyano-N- (2,4-dichlorophenyl)-3-(1H-indazol-5-yl)acrylamide 
 
 
 
Indazole-5-carboxaldehyde (0.016 g, 0.109 mmol) was used in the same previous aldol 
reaction conditions (0.024 g, 62%).; 1H NMR (500 MHz, DMSO-d6) 13.53 (s, 1 H, ArNH), 
10.07 (s, 1 H, NH), 8.51 (s, 1 H, ArH), 8.45 (s, 1 H, C=CH), 8.32 (s, 1 H, ArH), 8.09 (dd, 
J = 1.7, 8.9 Hz, 1 H, ArH), 7.75 (m, 2 H, ArH), 7.68 (d, J = 8.7 Hz, 1 H, ArH), 7.49 (dd, J 
= 2.4, 8.6 Hz, 1 H, ArH); 13C NMR (126 MHz, DMSO-d6) δ 161.26, 153.41, 136.12, 
51 
 
134.11, 131.44, 130.32, 129.59, 129.09, 128.28, 127.32, 126.90, 124.72, 123.63, 117.32, 
111.74, 109.99, 102.96. HRMS: [M-H]- calculated: 355.0159, found: 355.0169. 
 
General Procedure for Amide Coupling: 
(E)-3-(3-bromo-4-hydroxy-5-methoxyphenyl)-N-(4-chlorophenyl)-2-
cyanoacrylamide 
 
 
 
Previously synthesized (E)-3-(3-bromo-4-hydroxy-5-methoxyphenyl)-2-cyanoacrylic acid 
(0.016 g, 0.053 mmol) and 4-chloroaniline (0.068 g, 10 eq) was dissolved in 0.5 mL of 
THF. N,N′-diisopropylcarbodiimide (DIC, 8.2 µL, 1 eq) was added slowly and the solution 
was stirred at room temperature for 2.5 hours. Afterwards, the reaction mixture was diluted 
with 10 mL of DCM and the organic layer was extracted with 6 N HCl (3 x 10 mL), 
saturated NaHCO3 (3 x 10 mL), and brine (1 x 10 mL) sequentially. The organic layer was 
then dried with MgSO4 and concentrated in vacuo. The resulting crude solid was then 
redissolved into DCM with 0.1% AcOH and purified by silica flash chromatography using 
DCM and 0.1% AcOH. A yellow solid was obtained after concentration in vacuo (5 mg, 
23%). Rf 0.8 (100:0.01 DCM/AcOH). 1H NMR (500 MHz, DMSO-d6) δ 10.82 (br, 1 H, 
OH), 10.41 (s, 1 H, NH), 8.15 (s, 1 H, C=CH), 7.85 (d, J = 1.9 Hz, 1 H, ArH), 7.70 (m, 3 
H, ArH), 7.43 (m, 2 H, ArH), 3.89 (s, 1 H, OCH3);  13C NMR (125 MHz, DMSO-d6) δ 
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160.83, 149.95, 148.31, 148.23, 137.31, 128.68, 128.15, 127.94, 123.82, 122.11, 116.67, 
112.30, 109.63, 103.76, 56.30. HRMS: [M-H]- calculated: 404.9647, found: 404.9661.  
 
(E)-3-(3-bromo-4-hydroxy-5-methoxyphenyl)-N-(4-bromophenyl)-2-
cyanoacrylamide 
 
4-bromoaniline (0.288 g, 10 eq, 1.68 mmol) was used in the same previous amide coupling 
reaction conditions (0.020 g, 26%).; 1H NMR (500 MHz, CD3CN-d3) δ 8.58 (s, 1 H, NH), 
8.10 (s, 1 H, C=CH), 7.78 (d, J = 2.0 Hz, 1 H, ArH), 7.70 (d, J = 2.0 Hz, 1 H, ArH), 7.59 
(m, 2 H, ArH), 7.52 (m, 2 H, ArH), 3.93 (s, 3 H, OCH3);  13C NMR (125 MHz, DMSO-d6) 
δ 160.86, 149.70, 149.43, 148.38, 137.69, 131.41, 128.42, 122.93, 122.38, 116.71, 115.86, 
112.20, 109.88, 102.62, 56.17. HRMS: [M-H]- calculated: 448.9142, found: 448.9157 
 
(E)-3-(3-bromo-4-hydroxy-5-methoxyphenyl)-2-cyano-N-(p-tolyl)acrylamide 
 
 
 
p-Toluidine (0.180 g, 10 eq, 1.68 mmol) was used in the same previous amide coupling 
reaction conditions (0.023 g, 36%).; 1H NMR (500 MHz, CD3OD) δ 8.03 (s, 1 H, C=CH), 
7.73 (s, 2 H, ArH), 7.49 (m, 2 H, ArH), 7.17 (m, 2 H, ArH), 3.91 (s, 3 H, OCH3), 2.33 (s, 
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3 H, ArCH3);  13C NMR (125 MHz, DMSO-d6) δ 161.01, 152.51, 149.13, 148.86, 135.92, 
132.91, 129.31, 128.92, 120.70, 120.46, 117.53, 111.83, 110.74, 99.88, 55.96, 20.37. 
HRMS: [M-H]- calculated: 385.0193, found: 385.0208. 
 
(E)-3-(3-bromo-4-hydroxy-5-methoxyphenyl)-N-(4-(tert-butyl)phenyl)-2-
cyanoacrylamide 
 
 
 
4-tert-butylaniline (0.268 mL, 10 eq, 1.68 mmol) was used in the same previous amide 
coupling reaction conditions (0.040 g, 56%).; 1H NMR (500 MHz, DMSO-d6) δ 10.14 (s, 
1 H, NH), 8.10 (s, 1 H, C=CH), 7.81 (d, J = 1.9 Hz, 1 H, ArH), 7.69 (d, J = 2.0 Hz, 1 H, 
ArH), 7.54 (m, 2 H, ArH), 7.33 (m, 2 H, ArH), 3.86 (s, 3 H, OCH3), 1.23 (s, 9 H, C(CH3)3);  
13C NMR (125 MHz, DMSO-d6) δ 149.36, 148.19, 148.08, 146.60, 135.60, 127.90, 125.19, 
123.86, 120.31, 116.62, 112.28, 109.53, 104.10, 56.24, 33.98, 31.06. HRMS: [M-H]- 
calculated: 427.0663, found: 427.0688. 
 
(E)-3-(3-bromo-4-hydroxy-5-methoxyphenyl)-2-cyano-N-(4-
(trifluoromethyl)phenyl)acrylamide 
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4-(Trifluoromethyl)aniline (0.211 mL, 10 eq, 1.68 mmol) was used in the same previous 
amide coupling reaction conditions (0.033 g, 45%).; 1H NMR (500 MHz, DMSO-d6) δ 
10.61 (s, 1 H, NH), 8.19 (s, 1 H, C=CH), 7.90 (d, J = 8.5 Hz, 2 H, ArH), 7.86 (d, J = 1.9 
Hz, 1 H, ArH), 7.74 (d, J =  8.7 Hz, 2 H, ArH), 7.72 (d, J = 2.0 Hz, 2 H, ArH), 3.90 (s, 3 
H, OCH3); 13C NMR (125 MHz, DMSO-d6) δ 171.76, 161.14, 150.12, 148.58, 148.25, 
141.90, 128.24, 125.89, 125.86, 123.55, 120.35, 116.46, 112.31, 109.63, 103.43, 56.24, 
20.89. HRMS: [M-H]- calculated: 438.9911, found: 438.9950. 
 
(E)-3-(3-bromo-4-hydroxy-5-methoxyphenyl)-2-cyano-N-(naphthalen-2-
yl)acrylamide 
 
 
 
2-Naphthylamine (0.120 g, 10 eq, 0.840 mmol) was used in the same previous amide 
coupling reaction conditions (0.006 g, 17%).; 1H NMR (500 MHz, DMSO-d6) 10.81 (br s, 
1 H, OH), 10.49 (s, 1 H, NH), 8.30 (d, J = 2.0 Hz, 1 H, ArH), 8.20 (s, 1 H, C=CH), 7.91 
(d, J = 9.0 Hz, 1 H, ArH), 7.87 (m, 3 H, ArH), 7.73 (m, 2 H, ArH), 7.47 (m, 2H, ArH), 3.90 
(s, 3 H, OCH3); 13C NMR (101 MHz, DMSO-d6) δ 161.02, 149.75, 148.42, 148.28, 135.99, 
133.20, 130.22, 128.38, 128.21, 127.53, 127.51, 126.56, 125.15, 123.80, 120.81, 117.03, 
116.82, 112.25, 109.70, 103.90, 56.31. HRMS: [M-H]- calculated: 421.0193, found: 
421.0121.  
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(E)-N-([1,1'-biphenyl]-3-yl)-3-(3-bromo-4-hydroxy-5-methoxyphenyl)-2-
cyanoacrylamide 
 
 
 
3-Aminobyphenyl (0.142 g, 10 eq, 0.840 mmol) was used in the same previous amide 
coupling reaction conditions (0.017 g, 44%).;  1H NMR (500 MHz, DMSO-d6) 10.37 (s, 1 
H, NH), 8.19 (s, 1 H, C=CH), 7.98 (t, J = 1.8 Hz, 1 H, ArH), 7.87 (d, J = 2.0 Hz, 1 H, ArH), 
7.73 (d, J = 2.1 Hz, 1 H, ArH), 7.70 (dt, J = 1.9, 7.5 Hz, 1 H, ArH), 7.65 (m, 2 H, ArH), 
7.50 (m, 2 H, ArH), 7.46 (m, 2 H, ArH), 7.40 (m, 1 H, ArH), 3.90 (s, 3 H, OCH3); 13C 
NMR (101 MHz, DMSO-d6) δ 161.27, 150.28, 148.75, 148.69, 141.17, 140.36, 139.36, 
129.85, 129.49, 128.60, 128.15, 127.09, 124.30, 123.07, 119.99, 119.32, 117.21, 112.71, 
110.10, 104.35, 56.75. HRMS: [M-H]- calculated: 447.0350, found: 447.0253. 
 
3-(3-bromo-4-hydroxy-5-methoxyphenyl)-2-cyano-N-(2,4-
dichlorophenyl)propanamide 
 
 
 
Palladium on carbon (5 mg, 10% wt % loading) was added to a round bottom flask and 
purged with argon. Previously synthesized (E)-3-(3-bromo-4-hydroxy-5-methoxyphenyl)-
2-cyano-N-(2,4-dichlorophenyl)acrylamide (0.050 g, 0.113 mmol) was dissolved into a 
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minimal amount of dry acetone and added to the flask containing Pd/C. A balloon filled 
with H2 was added and the reaction was stirred for 18 hours at room temperature. The 
mixture was filtered through Celite to remove Pd/C. The mixture was purified by 
preparative TLC using 4:6 EtOAc/hexanes (Rf 0.2) (0.005 g, 10%). 1H NMR (500 MHz, 
CD3CN) δ 8.34 (s, 1 H, NH), 7.87 (d, J = 8.8 Hz, 1 H, ArH), 7.53 (d, 1 H, ArH), 7.35 (dd, 
J = 2.4, 8.8 Hz, 1 H, ArH), 7.05 (d, J = 1.8 Hz, 1 H, ArH),  6.91 (d, J = 1.8 Hz, 1 H, ArH), 
4.10 (t, J = 7.5 Hz, 1 H, CHCN), 3.82 (s, 1 H, OCH3), 3.20 (m, 2 H, ArCH2); 13C NMR 
(100 MHz, CD3CN) δ 164.89, 148.86, 144.00, 133.81, 131.63, 130.11, 129.57, 128.66, 
127.74, 126.52, 125.94, 112.78, 108.77, 57.09, 42.07, 36.41. HRMS: [M-H]- calculated: 
440.9414, found: 440.9434. 
 
Methyl 4-amino-3-bromo-5-methoxybenzoate 
 
 
 
This compound was prepared as previously reported. (Chem-Eur. J. 17(49), 13665-13669, 
2011.) Methyl 4-amino-3-methoxybenzoate (0.500 g, 2.76 mmol) was used as previously 
described (0.710 g, 99%).; 1H NMR (500 MHz, CDCl3) δ 7.81 (d, J = 1.7 Hz, 1 H, ArH), 
7.38 (d, J = 1.6 Hz, 1 H, ArH), 4.65 (s, 2 H, NH2), 3.91 (s, 3 H, COOCH3), 3.87 (s, 3 H, 
OCH3); HRMS: [M+H]- calculated: 259.9917, found: 259.9916. 
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(4-amino-3-bromo-5-methoxyphenyl)methanol 
 
 
LiAlH4 (0.052 g, 1.37 mmol, 2 eq) was added to a round bottom flask under argon and 
placed into an ice bath. Dry diethyl ether (1.5 mL) was slowly added to the flask with 
stirring. A solution of the previously synthesized methyl 4-amino-3-bromo-5-
methoxybenzoate (0.179 g, 0.688 mmol) and diethyl ether (1.5 mL) was added dropwise 
to the flask over 15 minutes. The ice bath was then removed and the reaction was allowed 
to stir for 2 hours at room temperature. After 2 hours, the reaction was quenched by the 
slow addition of EtOAc (1.5 mL). The reaction mixture was then poured into water (9 mL) 
and extracted with three portions of EtOAc (15 mL). The combined organic layers were 
dried with MgSO4 and concentrated in vacuo. The resulting crude solid was then 
redissolved in 4:6 EtOAc/Hex and purified by silica flash chromatography using 6:4 
EtOAc/Hex. The resultant compound was a clear, yellow oil (0.134 g, 84%). Rf 0.6 (6:4 
EtOAc/Hex). 1H NMR (500 MHz, CDCl3) δ 6.93 (d, J = 1.8 Hz, 1 H, ArH), 6.67 (d, J = 
1.7 Hz, 1 H, ArH), 4.45 (s, 2 H, CH2OH), 4.14 (s, 2 H, NH2), 3.79 (s, 3 H, OCH3), 2.92 
(br, 1 H, OH); 13C NMR (125 MHz, CDCl3) δ 147.62, 133.93, 131.56, 122.90, 108.40, 
108.31, 64.73, 55.94. HRMS: [M-H]- calculated: 229.9822, found: 229.9821. 
 
4-amino-3-bromo-5-methoxybenzaldehyde 
 
 
58 
 
Previously synthesized (4-amino-3-bromo-5-methoxyphenyl)methanol (0.131 g, 0.578 
mmol) was dissolved into dry DMF (3.39 mL). MnO2 (0.277 g, 5 eq) was added and the 
reaction mixture was stirred for 50 hours at room temperature. The reaction mixture was 
then filtered through Celite and rinsed with EtOAc (10 mL). The reaction mixture was then 
extracted with water (3 x 50 mL) to remove DMF. The organic layer was then dried with 
MgSO4 and concentrated in vacuo. The resultant compound was a tan solid (0.116 g, 88%). 
1H NMR (500 MHz, CDCl3) δ 9.64 (s, 1 H, CHO), 7.50 (d, J = 1.5 Hz, 1 H, ArH), 7.21 (s, 
J = 1.4 Hz, 1 H, ArH), 4.88 (s, 2 H, NH2), 3.90 (s, 3 H, OCH3); 13C NMR (125 MHz, 
CDCl3) δ 189.34, 146.94, 141.20, 130.25, 127.24, 107.13, 106.31, 56.14. HRMS: [M+H]- 
calculated: 229.9811, found: 229.9812. 
 
(E)-3-(4-amino-3-bromo-5-methoxyphenyl)-2-cyano-N-(2,4-
dichlorophenyl)acrylamide 
 
 
 
Previously synthesized 4-amino-3-bromo-5-methoxybenzaldehyde (0.048 g, 0.208 mmol) 
was used in the same previous aldol reaction conditions (0.081 g, 88%).; 1H NMR (500 
MHz, DMSO-d6) δ 9.77 (s, 1 H, NH), 8.13 (s, 1 H, C=CH), 7.84 (d, J = 1.7 Hz, 1 H, ArH), 
7.73 (d, J = 2.4 Hz, 1 H, ArH), 7.68 (d, J = 8.6 Hz, 1 H, ArH), 7.63 (d, J = 1.5 Hz, 1 H, 
ArH), 7.47 (dd, J = 2.4, 8.7 Hz, 1 H, ArH), 6.25 (s, 1 H, NH2), 3.87 (s, 3 H, OCH3); 13C 
NMR (126 MHz, DMSO-d6) δ 161.45, 151.62, 146.42, 141.74, 134.25, 131.09, 130.16, 
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129.83, 129.47, 128.55, 128.19, 120.31, 117.93, 110.97, 105.80, 98.83, 56.49. HRMS: [M-
H]- calculated: 437.9417, found: 437.9300. 
 
Small molecule HPLC Purification. Crude small molecule was dissolved into MeOH 
until saturation. Purification was achieved by using an Eclipse XDB-C18 column (9.4 x 
250 mm, Agilent) at a 5 mL/min flow rate with the following method on an Agilent 1100 
Series HPLC: Linear gradient of 70:30 MeCN:H2O to 88:12 MeCN:H2O for 8 minutes, 
followed by 100% MeCN for 2 minutes. The compound elution was monitored by 
absorbance at 254 nm. Collected fractions were pooled, flash frozen, and lyophilized. 
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MECHANISTIC AND FUNCTIONAL CHARACTERIZATION OF 
COMPOUND 37 
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C h a p t e r  4  
MECHANISTIC AND FUNCTIONAL CHARACTERIZATION OF 
COMPOUND 37 
Introduction 
An important part of any tool and/or drug discovery process includes assessment of 
the biological relevance and mechanism of action of the identified compound. This can be 
accomplished through characterization of specificity, mode of inhibition, and affected 
biological phenotypes.  Here, we adapted the fluorescence assay to characterize specificity 
against different sulfotransferases, kinetic analysis to understand the mode of inhibition, 
and various biochemical approaches to study the potential mechanism of action of 
compound 37. As proof of principle, we decided to examine the ability of 37 to affect the 
processes of astrogliosis. We tested the ability of 37 to inhibit the cell-surface expression 
CS-E on astrocytes, the key cell type involved in generating growth inhibitory CSPGs. 
Furthermore, we analyzed the disaccharide content of CSPGs secreted from astrocytes and 
determined that the treatment of astrocytes with 37 attenuated the growth inhibitory effects 
of the secreted CSPGs. Compound 37 was then characterized in vitro and in vivo in 
pharmacokinetic models, including microsomal stability, cytochrome p450 inhibition, and 
intravenous injection into rats.   
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Results and Discussion 
To determine the specificity of these inhibitors, we utilized the fluorescent, 
enzyme-coupled screen because it allowed for an adaptable method to compare 
sulfotransferases with different substrates. When screened in the fluorescence assay, there 
was a clear dichotomy between the tested sulfotransferases with glycosaminoglycan 
substrates versus aromatic substrates (Figure 4.1). In this assay, 37 had an IC50 = 2.43 µM 
versus Chst15, while against other closely related chondroitin sulfotransferases, Chst11 
and Ust, it had IC50’s of 2.45 and 2.02 µM respectively. Versus heparan sulfate 3-O 
sulfotransferase (Hs3st1), a sulfotransferase for HS GAGs, it also had a similar IC50 value 
of 2.51 µM. However, when 37 was tested against cytosolic sulfotransferases Sult1e1, 
Sult2b1a, and Sult2b1b, IC50’s increased 7.6- to 17.5-fold. Along with this, the coupled 
enzyme, Sult1c1, also a cytosolic sulfotransferase, showed no dose response. Due to the 
similarity of the substrates and the sequence homology amongst GAG sulfotransferases 
(26-81%),1-10 the result of 37 also inhibiting other glycosaminoglycan sulfotransferases 
was not completely unexpected. However, these compounds can still be valuable for the 
study of the biological roles of GAG sulfation as there are no reported cell-permeable, 
GAG sulfotransferase inhibitors. 
To study the mechanism of inhibition of Chst15 by 37 in greater detail, we utilized 
the fluorescent assay to examine the type of inhibition against CS-A and PAPS. Analysis 
of the kinetic data revealed that 37 displayed different modes of inhibition depending on 
the substrate. When CS-A was the varied substrate, intersecting lines in the second 
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quadrant of the Lineweaver-Burk plot indicated a mixed mode of inhibition, where both 
Km and Vmax shifted as a result of the inhibitor being present with a Ki = 1.09 µM and Ki’  
 
 
 
 
 
 
 
 
 
 
= 2.14 µM. In contrast, when PAPS was the varied substrate, lines intersecting on the y-
axis signified a competitive mode of inhibition with a Ki = 2.58 µM (Figure 4.2 and Table 
4.1). The inhibitor’s competitive nature against PAPS offers an explanation for its cross 
reactivity with other sulfotransferases.  
We hypothesized that the α,β-unsaturated acrylamide moiety could serve as an 
electrophilic site for a nucleophilic amino acid side chain. Indeed, compounds with similar 
cyanoacrylamide structures have been reported to inhibit noncatalytic cysteines on kinases  
Figure 4.1. Compound 37 selectively inhibits glycosaminoglycan sulfotransferases. 
Various glycosaminoglycan and cytosolic sulfotransferases were assayed against inhibitor 
37 using the fluorescence assay. Of the sulfotransferases tested, 37 was ~12-fold more 
selective for glycosaminoglycan sulfotransferases compared to cytosolic sulfotransferases. 
Values reported as the mean ± S.E.M (n = 3).    
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Ki = 1.43 mM  Ki = 0.77 µM  
Ki’ = 2.45 mM  
Figure 4.2. Steady-state kinetic analysis reveals competitive and mixed modes of Chst15 
inhibition by 37. Initial reaction velocities were determined by the fluorescence assay with 
varying substrate concentrations, (A) CS-A and (B) PAPS, at different concentrations of 37. 
Double reciprocal plots (Lineweaver-Burk) showed 37 is a competitive inhibitor of PAPS and 
a mixed inhibitor of CS-A. Values represent the mean ± S.E.M. (n = 3). Ki and Ki’ parameters 
were derived from a secondary plot of Km/V versus [37] for (C) CS-A and (D) PAPS. (E) Ki’ 
was derived from a secondary plot of 1/V versus [37] for CS-A. 
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via a “reversible covalent” mechanism.11,12 Consistent with this mechanism, we observed 
a reduction in the prominent UV-visible absorption band of the cyanoacrylamide 37 (λmax 
= 378 nm) when the compound was incubated with a surrogate nucleophile, β-
mercaptoethanol (βME), suggesting the formation of covalent adduct 56 (Figure 4.3A and 
4.3B). Formation of this adduct was rapidly reversed when 37 was diluted 10-fold into 
phosphate buffered saline (PBS) without βME (Figure 4.3C). Further evidence for a 
reversible thioether adduct was obtained by 1H NMR spectroscopy (Figure 4.3D). 
Appearance of an aliphatic β-proton in adduct 56 was witnessed upon incubation of 37 
with βME. The integrated peak ratio between this proton and the olefin proton in 37 
indicated a substrate to adduct ratio of 43:57. Two-fold dilution into PBS shifted this ratio 
to 63:37, indicating reversion of this equilibrium. In enzymatic activity assays, longer pre- 
 
Table 4.1. Kinetic parameters of inhibition for Chst15. Kinetic parameters were 
determined by measuring the initial reaction velocities at varying substrate concentrations 
in the presence of 37 at concentrations of 0, 1, 5, and 10 µM. kcat and Km were determined 
from Lineweaver-Burk plots. Ki and Ki’ were derived from secondary plots of Km/V versus 
[37] or 1/V versus [37], respectively. 
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Figure 4.3. Compound 37 exhibits reversible-covalent inhibitor properties when using β-
mecaptoethanol (βME) as a model nucleophile. (A) Conjugate addition reaction of βME 
with 37. (B) UV-Vis absorption (λmax = 378 nm) was lost upon incubation of 37 with βME 
suggesting conjugation. (C) However, 10-fold dilution of B with PBS led to a reversal in 
the equilibrium when compared to the dilution of B with βME. (D) 1H-NMR showing the 
appearance of a newly formed aliphatic proton (red) after incubation with βME indicated 
conjugation. Upon dilution, the ratio of the integrated olefin (blue) and aliphatic proton 
signaled a shift in the equilibrium back to 37.  
A  
B  C
D  
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incubation times with the inhibitor led to a higher observed inhibition, supporting its 
covalent nature (Figure 4.4A). Furthermore, greater enzyme activity was restored with 10-
fold dilution, indicating a dependence only on final concentration and thus supporting its 
reversibility (Figure 4.4B). 
The ability to inhibit GAG sulfation after CNS injury could have exciting 
implications for neural regeneration (Figure 4.5). Studies have established that the CS-E 
sulfation motif is upregulated on CSPGs after injury and inhibits the growth of sensory 
axons.13,14 To explore the effects of these small molecules in a cellular context, we decided 
to examine if 37 treatment could lead to the hypothesized decrease in CS sulfation. To this 
Figure 4.4. 37 inhibitory activity depends on pre-incubation time and shows reversibility. 
(A) Longer pre-incubation times result in greater inhibition by 37, supporting irreversible 
properties. The compound is out competed by the substrates CS-A (1 mM) and PAPS (30 
µM). (B) 37 inhibitory activity is not dilution resistant, supporting its reversibility. Chst15 
is pre-incubated with 37 at the indicated concentrations (12.5 µM, 25 µM, 50 µM, 100 
µM). However, a loss of inhibitory activity is seen in samples diluted 10-fold. This is only 
expected for reversible compounds where inhibitory activity is only dependent on the final 
concentration.  
A  B 
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end, we first treated NIH3T3 fibroblasts and Neu7 astrocytes with 37 and 
immunofluorescently stained with a monoclonal CS-E antibody developed previously.13 
Quantification of the images revealed a significant, dose-dependent decrease in CS-E  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
staining when treating both cell types with 37 as compared to untreated cells (Figure 4.6). 
The effect was maximal at 25 µM of 37. Likewise, unsurprisingly, treatment also decreased 
HS expression seen when staining with a monoclonal HS antibody (Figure 4.7). These 
decreases in staining were also recapitulated by treatment of both cell types with sodium 
chlorate, a PAPS synthetase inhibitor often used as a universal sulfation inhibitor. 
Figure 4.5. Representation of astrogliosis after neuronal injury and the potential 
therapeutic mechanism of small molecule treatment. Reactive astrocytes release over-
sulfated CSPGs that inhibits axonal growth in response to neuronal insult. Small-molecule 
treatment at the site of injury may reduce the sulfation of secreted CSPGs and potentiate 
axonal regrowth.  
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However, its global effects on sulfation, oxidative properties, and use in millimolar 
concentrations precludes its therapeutic application, again highlighting the significance of 
these sulfotransferase inhibitors.15,16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Treatment of NIH/3T3 fibroblasts and Neu7 astrocytes with 37 leads to a 
significant, dose-dependent decrease in CS-E expression. Cells were grown in the presence 
of inhibitors for 40 hours and stained with a monoclonal CS-E antibody (green) and DAPI 
(blue, astrocytes only). Cells were imaged and quantified by fluorescence microscopy (scale 
bar = 100 μM). Treatment of inhibitors were compared with untreated cells (One-way 
ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001). Quantification from three experiments is 
shown (n = 20-100 cells per experiment). 
A  
B  
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After spinal cord injury, reactive astrocytes enter the site of injury and secrete 
CSPGs as a means to sequester further damage. The Neu7 astrocytic cell line has been 
previously characterized to secrete neuronal growth inhibiting CSPGs.17,18 To characterize 
the secreted CSPGs, we purified them from Neu7 conditioned media, digested them with 
chondroitinase ABC (ChABC), and then analyzed their disaccharide content by reversed-
phase ion-pair high-performance liquid chromatography (RPIP-HPLC).19 CSPGs collected 
from astrocytes treated with 37 showed a clear decrease in overall sulfation. Not 
unexpectedly, each CS sulfation motif was affected to varying degrees, with the CS-E 
disaccharide seeing the largest decrease of 67.8% ± 11.0% at 25 µM of 37 as compared to 
Figure 4.7. Treatment of NIH/3T3 fibroblasts with 37 leads to a significant, dose-dependent 
decrease in HS expression. NIH/3T3 fibroblasts were grown in the presence of inhibitors for 
40 hours and stained with a polyclonal HS antibody (green) and DAPI (blue). Cells were 
imaged and quantified by fluorescence microscopy (scale bar = 100 μM). Treatment of 
inhibitors were compared with untreated cells (One-way ANOVA, *P < 0.05, **P < 0.01, 
***P < 0.001). Quantification from three experiments is shown (n = 20-100 cells per 
experiment). 
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CSPGs from untreated cells (Figure 4.8 and Table 4.2). These studies indicated that the 
discovered inhibitors decreased sulfation on both surface-expressed and secreted CSPGs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. CSPGs from Neu7 astrocytes treated with inhibitor 37 show decreased levels 
of CS-E and other sulfation motifs. CS disaccharide composition was analyzed by reverse 
phase ion-pairing high pressure liquid chromatography (RPIP-HPLC). CS-D was not 
detected. uCS, unsulfated CS. Values are normalized to the disaccharide content on CSPGs 
from untreated astrocytes and are reported as the mean ± S.E.M. (n = 3). 
Table 4.2. Quantification of the percent disaccharide composition of CSPGs secreted from 
untreated and treated astrocytes. CS disaccharide composition was analyzed by reverse 
phase ion-pairing high pressure liquid chromatography (RPIP-HPLC). CS-D was not 
detected. uCS, unsulfated CS. Values are reported as the mean ± S.E.M. (n = 3). 
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As a potential therapeutic agent, treatment of the site of injury would generate an 
environment in which all cell types (neurons, astrocytes, oligodendrocytes, microglia) 
would encounter the compound.20 While the main target for the inhibitors are the reactive 
astrocytes secreting CSPGs, it was important to determine the effects on neuronal growth 
directly. When treated with inhibitors directly, P5 rat dorsal root ganglion neurons (DRGs) 
did not show any significant changes in neurite outgrowth (Figure 4.9). Interestingly, 
compound 5 potentially shows slight growth promoting effects, which agrees with its 
previously reported neuroprotective activity by inhibiting cRaf.21     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. DRG treatment with 37 leads to no significant effect in neurite outgrowth. P5 rat 
DRGs were grown in the presence of inhibitors for 24 hours and imaged by fluorescence 
microscopy. DRG outgrowth with inhibitor treatment was compared with untreated cells 
(One-way ANOVA). Quantification from three experiments is shown (n = 20-80 cells per 
experiment). 
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As an in vitro model of the spinal cord environment post-injury, DRGs were grown 
on a substratum coated with the CSPGs purified from Neu7 astrocytes. To our delight, 
compared to DRGs grown on CSPGs from untreated Neu7 astrocytes, there was a 
significant, dose-dependent promotion of neurite outgrowth of up to 30.7% of DRGs grown 
on CSPGs from 37 treated astrocytes (Figure 4.10). In fact, treatment with 25 µM 37 
reverses the inhibitory effects produced by these CSPGs. This dose-dependent trend in 
outgrowth promotion was also seen with sodium chlorate treatment, highlighting again that 
sulfation plays key role in CSPG-mediated axonal inhibition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. The inhibitory effects of CSPGs secreted from Neu7 astrocytes are attenuated 
by treatment of the cells with 37 or the general sulfation inhibitor sodium chlorate. P5 rat 
DRGs were grown on substrata coated with or without CSPGs isolated from astrocytes 
following treatment as indicated. Cells were imaged by fluorescence microscopy (scale bar 
= 50 μm), and neurite outgrowth quantified. Data were normalized relative to DRGs grown 
on CSPGs from untreated astrocytes. One-way ANOVA, *P < 0.05, **P < 0.01, ***P < 
0.001. Quantification from three experiments is shown (n = 20-80 neurons per experiment). 
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Similarly, in another in vitro model of the glial scar environment, we examined if 
the inhibitor treatment of astrocytes could reduce the repulsion of axons seen when 
encountering a boundary created by secreted CSPGs in a boundary assay format. As 
hypothesized, CSPGs from untreated astrocytes formed an inhibitory zone that was highly 
repellent to DRG axons (Figure 4.11). In contrast, axons more freely crossed into 
boundaries with CSPGs treated with 37 as there was no significant difference in axon 
crossing compared to a boundary containing no CSPGs.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. CSPGs from astrocytes treated with 37 repel fewer neurites compared to 
CSPGs from untreated astrocytes. A boundary assay was performed in which purified 
CSPGs from Neu7 astrocytes (5 μg/mL) or PBS control were mixed were Texas Red and 
spotted on poly-lysine coated coverslips. P5 rat DRGs were grown on the coverslips and 
quantified for their ability to cross the CSPG-containing boundary (scale bar = 50 μm). 
CSPGs from inhibitor treated astrocytes were significantly less inhibitory toward DRGs 
(25 μM 37, 25 mM NaClO3). One-way ANOVA, n.s. = not significant, *P < 0.05, **P < 
0.0001. Quantification from five experiments is shown (n = 20-40 neurons per 
experiment). 
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Table 4.4. In Vitro Cytochrome P450 Inhibition by 19 
CYP Isoform IC50 (µM) 
CYP2C9 0.7 ± 0.1 
CYP2D6 > 25 
CYP3A4 II > 25 
CYP3A4 I > 25 
 
As a prelude to conducting in vivo injury experiments, we tested 19 and 37 in in 
vitro liver microsomal stability and cytochrome p450 inhibition assays to profile 
absorption, distribution, metabolism, and elimination (ADME) properties. The compound 
showed good stability in human, mouse, and rat liver microsomes based on intrinsic 
clearance (Table 4.3). Encouragingly, of the four cytochrome p450 isoforms tested, three 
were not appreciably inhibited at compound 19 concentrations as high as 25 µM (Table 
4.4). The pharmacokinetic (PK) properties of 37 were also evaluated directly in rats. After 
intravenous injection of compound 37 at a dose of 3.0 mg/kg, the compound had a moderate 
clearance of 20.61 mL/min/kg, moderate volume of distribution of 0.97 L/kg, and short 
terminal half-life of 1.58 h (Table 4.5). This data seemed to indicate that using a direct, as 
opposed to intravenous, application of the drug may be more efficacious for future in vivo 
injury studies.   
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Conclusion 
In conclusion, here we have described the in vitro and in vivo characterization of 
the most potent, optimized compound, 37. We showed that compound 37 did not only 
inhibit Chst15, but also other similarly related glycosaminoglycan sulfotransferases 
involved in the biosynthesis of HS and CS. Kinetic analysis showed that the compound 
inhibited PAPS in a competitive fashion, which offers an explanation for the nonspecificity 
seen against other GAG sulfotransferases. Also, it was shown that compound 37 likely 
inhibits through a unique “reversible-covalent” mechanism based on its reactivity with a 
model nucleophile and time-dependent inhibition. Excitingly, when used in a cellular 
context, the inhibitor was able to reduce the sulfation of cell-surface expressed and secreted 
GAGs. The ability of these sulfated GAGs to potentiate neuronal inhibition was 
significantly decreased when they were secreted from inhibitor treated astrocytes. With its 
proven ability to inhibit GAG sulfation and in preparation of further in vivo collaborations, 
we determined that the PK parameters were good in vitro, while in vivo tests suggested 
direct application of the inhibitor may be most efficacious. Ongoing in vivo collaborations 
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to test the molecule’s biological relevance in neuronal injury models will be an important 
next step in the development of this tool into a potential therapeutic.            
 
Experimental Methods 
Expression and Purification of Sult2b1a and Sult2b1b. BL21(DE3) (Novagen) 
harboring the pGEX-6P-3-Sult2b1a or pGEX-6P-3-Sult2b1b constructs were kindly 
provided by Dr. Lars Pedersen (NIEHS/NIH). Cells were grown in LB medium (1L) at 
37°C. When cells reached an OD600 of 0.8, cells were moved to 16°C for 30 minutes. 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the cells at the final 
concentrations of 0.2 mM after the 30 minutes and cells were incubated for an additional 
18 hours at 16°C. The pelleted cells were lysed in cold PBS (10 mM Na2HPO4, 1.8 mM 
KH2PO4 pH 7.3, 140 mM NaCl, 2.7 mM KCl, and 1x CompleteTM protease inhibitors 
(Roche) by sonication. After centrifugation, the clarified lysate was added to pre-
equilibrated glutathione Sepharose 4B resin beads (GE Healthcare) and incubated at 4°C 
for 1 hour with end-over-end rotation. The beads were then washed 4 times with a buffer 
containing cold PBS and eluted with a buffer containing 50 mM Tris pH 8.0 and 10 mM 
reduced glutathione. After SDS-PAGE analysis, the purified protein was concentrated with 
a 30,000 Da molecular weight cut-off (MWCO) spin filter (Millipore), buffer exchanged 
into PBS and 50% glycerol, and stored at -20°C. 
 
Expression and Purification of Sult1a1, Chst11, and Ust. BL21(DE3)RIL (Stratagene) 
harboring the pET28a-Sult1a1 construct and Origami B(DE3) (Novagen) harboring the 
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pET32b-hChst1172-352 or pET32b-hUst84-406 constructs were kindly provided by Dr. Jian 
Liu (UNC-Chapel Hill). Cells were grown in LB medium (1L) at 37°C. When cells reached 
an OD600 of 0.8, cells were moved to 22°C for 30 minutes. Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to the cells at the final concentrations of 0.2 mM 
after the 30 minutes and cells were incubated for an additional 18 hours at 22°C. The 
pelleted cells were lysed in a cold buffer containing 25 mM Tris pH 7.5, 500 mM NaCl, 
10 mM imidazole and 1x EDTA-free CompleteTM protease inhibitors (Roche) by 
sonication. After centrifugation, the clarified lysate was added to pre-equilibrated Ni-NTA 
resin beads (Qiagen) and incubated at 4°C for 1 hour with end-over-end rotation. The beads 
were then washed 3 times with a buffer containing 25 mM Tris pH 7.5, 500 mM NaCl, 10 
mM imidazole, washed 1 time with 25 mM Tris pH 7.5, 500 mM NaCl, 50 mM imidazole 
and eluted with a buffer containing 25 mM Tris pH 7.5, 500 mM NaCl, 250 mM imidazole. 
After SDS-PAGE analysis, the purified protein was concentrated with a 30,000 Da 
molecular weight cut-off (MWCO) spin filter (Millipore), buffer exchanged into 25 mM 
Tris pH 7.5, 500 mM NaCl and 50% glycerol, and stored at -20°C. 
 
96-Well Plate Enzyme-Coupled, Fluorescent Assay. For full assay, the substrates PAPS 
and CS-A (Sigma) were added to a solution containing 100 mM Tris pH 7.6, 1 mM β-
mercaptoethanol, and 5 mM 4-methylumbelliferyl sulfate at a concentration of 30 µM and 
1 mM, respectively, to a total volume of 74 µL. 5 µL of Sult1c1 (2 mg/mL) was added to 
the mixture and incubated at 37°C for 1 hour. 20 µL of Chst15 (1 mg/mL), pre-incubated 
with 1 µL of DMSO or inhibitor stock for 30 minutes, was then added to the mixture to 
initiate the reaction. The 96-well plate was read using either a Victor3 Plate Reader (Perkin 
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Elmer) or Flexstation 3 (Molecular Devices) at excitation and emission wavelengths of 360 
nm and 449 nm respectively.  
For the counter screen, the substrates PAPS and CS-A (Sigma) were also added to 
a solution containing 100 mM Tris pH 7.6, 1 mM β-mercaptoethanol, and 5 mM 4-
methylumbelliferyl sulfate at a concentration of 30 µM and 1 mM, respectively, to a total 
volume of 75 µL. The reaction was initiated by adding a mixture of 5 µL of Sult1c1, 19 
µL of 100 mM Tris pH 7.6, and 1 µL of DMSO or inhibitor stock that has been pre-
incubated at room temperature for 30 minutes.   
 For enzyme specificity determination, Chst15 was replaced with either Chst11, Ust, 
Hs3st1, Sult1e1, Sult2b1a, or Sult2b1b. Likewise, CS-A was replaced with unsulfated 
chondroitin (Seikagaku), CS-C (Sigma), heparan sulfate (Neoparin), β-estradiol (Sigma), 
5-pregnen-3β-ol-20-one (Sigma), or cholesterol (Sigma) and used with their respective 
enzymes at 1 mM. IC50’s were determined by varying the inhibitor concentration and fit to 
a Michaelis-Menten model by Kaleidagraph (version 4.1.2). 
 For Chst15 kinetic analysis, reactions were performed in triplicate with varying 
substrate PAPS (10 µM to 200 µM) or CS-A (0.5 mM to 10 mM) concentrations. Product 
formation was monitored for 10 minutes and kinetic parameters were determined from 
Lineweaver-Burk, Km/V versus [inhibitor], and 1/V versus [inhibitor] plots. 
 
Cell Culture. NIH/3T3 fibroblasts and Neu7 astrocytes were grown in DMEM medium 
supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, and 0.1 mg/mL 
streptomycin (Gibco). Cells were passaged and dissociated with 0.25% trypsin (Life 
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Technologies). Cells were incubated in a 5% CO2 humidified chamber at 37°C. NIH/3T3 
fibroblasts were obtained from American Type Culture Collection (ATCC) and Neu7 
astrocytes were generously gifted by Dr. Herbert Geller (NIH).   
 
CS/HS Expression by Immunofluorescence. NIH/3T3 fibroblasts or Neu7 astrocytes 
were seeded at 4,000 cells/cm2 and grown in media premixed with inhibitors diluted from 
a 100x DMSO stock solution. After 48 hours, the media was aspirated and cells were fixed 
with 4% paraformaldehyde (PFA) for 15 minutes at room temperature. For chondroitinase 
ABC (ChABC) background determination, cells were treated with ChABC (Seikagaku) at 
a final concentration of 2 mU/µL in 33 mM Tris, 33 mM NaOAc pH 8.0 for 20 minutes at 
37°C and 5% CO2 prior to fixing. For heparinase background determination, cells were 
treated with heparinase I and III (Sigma) and II (Sigma) at final concentrations of 1 mU/µL 
and 0.2 mU/µL respectively in 50 mM NaPi pH 7.0 for 20 minutes at 37°C and 5% CO2 
prior to fixing. Cells were rinsed twice with PBS and blocked with a solution containing 
1% BSA and 0.1% Triton X-100 in PBS for 30 minutes at room temperature. The primary 
antibody in a buffer containing 1% BSA and 0.1% Triton X-100 in PBS was then applied 
overnight at 4°C. For CS-E staining, a monoclonal mouse anti-CS-E antibody (1:250 
dilution) was used. For HS staining, a monoclonal mouse heparan sulfate antibody 
(Amsbio, 10E4, 1:100 dilution) was used. After, cells were again washed twice with PBS 
and incubated with an anti-mouse AF488 antibody ((Life Technologies, 1:1000 dilution) 
in a buffer containing 1% BSA and 0.1% Triton X-100 in PBS for 1 hour at room 
91 
 
temperature. Cells were washed twice with PBS, imaged under a Zeiss 700 confocal 
microscope, and quantified by ImageJ.  
 
CSPG Purification. Media from Neu7 astrocytes was collected 48 hours after treatment. 
The media was centrifuged at 4,000 x g for 10 minutes to remove cells and debris. Urea (2 
M, final) was added to the supernatant and incubated at 4°C for 1 hour. For each 10 mL of 
media, 2 mL of pre-equilibrated DEAE Sepharose beads were added to the supernatant and 
incubated at 4°C for 1 hour. The mixture was then added to a column and allowed to drain. 
The beads were then washed with a buffer containing 50 mM Tris pH 7.5, 2 mM EDTA, 2 
M urea, and 0.25 M NaCl. The CSPGs were eluted with a buffer containing 50 mM Tris 
pH 7.5, 2 mM EDTA, 2 M urea, and 2 M NaCl. The eluate was then dialyzed overnight at 
4°C into PBS using dialysis tubing with a 10,000-12,000 MWCO (Spectrum Labs). The 
samples were then concentrated using 50 kDa MWCO spin filters (Millipore) and uronic 
acid concentrations of the samples was determined by the carbazole assay.  
 
Disaccharide Analysis. CSPGs purified from Neu7 astrocytes were dialyzed into a buffer 
containing 100 mM Tris pH 7.5 using a spin filter with a 3,000 MWCO (Millipore). 150 
µL of a buffer containing 100 mM Tris pH 7.5, 0.5% SDS, and 10 mM CaCl2 was added 
to the CSPGs (50 µL). Pronase (Roche) was added to a final concentration of 2 mg/mL and 
the reaction was incubated at 37°C for 18 hours. The samples were boiled for 10 minutes 
and centrifuged at 12,000 x g for 10 minutes at room temperature. The supernatant was 
then added to a DEAE Sepharose (500 µL) column, washed 3 times with 1 mL of a buffer 
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containing 50 mM Tris pH 7.5, 2 mM EDTA, 2 M urea, and 0.25 M NaCl, and eluted with 
1.5 mL of a buffer containing 2 mM EDTA, 2 M urea, and 2 M NaCl. The eluate was buffer 
exchanged into a buffer containing 33 mM Tris and 33 mM NaOAc pH 8.0 using a spin 
filter with a 3,000 MWCO. The CSPGs (50 µL) were diluted to 200 µL with the same 
buffer. 50 mU of chondroitinase ABC (Seikagaku) was added to each CSPG sample and 
allowed to incubate at 37°C for 18 hours. The reaction was put into a 3,000 MWCO spin 
filter, centrifuged at 12,000 x g for 10 minutes and flowthrough was collected. This was 
repeated twice more by adding 200 µL of water to the retentate. The flowthroughs were 
pooled, analyzed by the carbazole assay, and lyophilized. For 2-aminoacridone (AMAC) 
conjugation, 5 µL of a solution containing 0.1 M AMAC in 3:18 glacial acetic acid:DMSO 
was added to 1 µg of CS disaccharide and incubated for 15 minutes at room temperature. 
5 uL of 1 M NaBH3CN was then added and the reaction was incubated for 4 hours at 45°C. 
The reaction was quenched with 1:1 DMSO:water and analyzed by HPLC with a Poroshell 
120 EC-C18 column (4.6 x 50 mm) with the following method at a flow rate of 1 mL/min 
and detection at 428 nm: A linear gradient of 98% 60 mM NH4OAc and 2% MeCN to 70% 
60 mM NH4OAc and 30% MeCN for 50 minutes, followed by 15 minutes of 98% 60 mM 
NH4OAc and 2% MeCN.  
 
Neurite Outgrowth Assays. For outgrowth in inhibitor studies, 96-well poly-lysine 
Cellware plates (BD BioCoatTM) were coated with laminin (10 ug/mL, Life Technologies) 
in Neurobasal medium (Life Technologies) for 2 hours at 37°C and 5% CO2. Dorsal root 
ganglia neurons (DRGs) were dissected from P5 Sprague Dawley rates, incubated in 0.25% 
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trypsin with EDTA for 15 minutes at 37°C, followed by collagenase (Worthington; 4 
mg/mL) for 15 minutes at 37°C, triturated to dissociate to single cell suspensions, filtered 
using a 40 µm cell strainer (Fisher) to remove nondissociated cells, and seeded at 
approximately 60,000 cells/cm2 in Neurobasal medium supplemented with B27 and 
GlutaMAXTM (Life Technologies). After 48 hours, the media was aspirated and cells were 
fixed with 4% paraformaldehyde (PFA) for 15 minutes at room temperature. A monoclonal 
rabbit anti-β3 tubulin antibody (1:1000 dilution, Cell Signaling (D71G9)) in a buffer 
containing 1% BSA and 0.1% Triton X-100 in PBS was then applied overnight at 4°C. 
After, cells were again washed twice with PBS and incubated with an anti-rabbit AF568 
antibody ((Life Technologies, 1:1000 dilution) in a buffer containing 1% BSA and 0.1% 
Triton X-100 in PBS for 1 hour at room temperature. Cells were washed twice with PBS, 
imaged under a Zeiss 700 confocal microscope, and quantified using MetaMorph software. 
 For inhibition studies using CSPGs derived from Neu7 astrocytes, glass coverslips 
were coated with poly-lysine in borate buffer pH 8.5 (0.5 mg/mL) overnight at 37°C and 
5% CO2, followed by laminin (10 ug/mL) in Neurobasal medium (Life Technologies) for 
2 hours at 37°C and 5% CO2, followed by CSPGs purified from Neu7 astrocytes (1 µg/mL 
based on uronic acid content) in PBS for 2 hours at 37°C and 5% CO2. DRGs were 
dissected, plated, imaged, and quantified as above. P-values were determined using one-
way ANOVA (n = 20-80 neurons per experiment) and the results from three experiments 
were shown. 
Boundary Assay. CSPGs purified from Neu7 astrocytes (5 µg/mL based on uronic acid 
content) were mixed with Texas Red (0.5 mg/mL; Life Technologies) in PBS, spotted on 
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poly-lysine and laminin (10 µg/mL) coated coverslips (3 µL), and incubated for 2 hours at 
37°C and 5% CO2. DRGs were dissected from P5 Sprague Dawley rates, incubated in 
0.125% trypsin with EDTA for 15 minutes at 37°C, followed by collagenase (Worthington; 
4 mg/mL) for 15 minutes at 37°C, triturated to dissociate to single cell suspensions, filtered 
using a 40 µm cell strainer (Fisher) to remove nondissociated cells and seeded at 
approximately 60,000 cells/cm2. Cells were cultured for 48 hours in Neurobasal medium 
supplemented with B27 and GlutaMAXTM (Life Technologies). After immunostaining for 
neurite outgrowth, axons growing toward and within 10 µm of the boundary were evaluated 
using a Zeiss 700 confocal microscope. The percentage of axons that crossed the boundary 
over the total axons was quantified. P-values were determined using one-way ANOVA (n 
= 20-40 neurons per experiment) and the results from five experiments were shown. 
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C h a p t e r  5  
INTRODUCTION TO O-GLCNAC AND STUDYING ITS ROLE IN 
STRUCTURE AND FUNCTION 
The addition of O-linked β-N-acetylglucosamine (O-GlcNAc) to serine or threonine 
residues of proteins is a key regulator of many physiological functions, ranging from 
nutrient sensing1,2 and insulin signaling3,4 to learning and memory.5,6 Post translational 
modification of proteins with O-GlcNAc is a unique form of glycosylation that occurs 
intracellularly and dynamically, akin to protein phosphorylation. Over 1000 proteins 
bearing the modification have been identified to date, ranging from kinases, structural 
proteins, and nuclear pore proteins to transcriptional machinery including RNA 
polymerase II.7 Dysregulation of the modification has also been linked to disease states 
such as cancer,4,8,9 diabetes,4,10 and Alzheimer’s.11,12 Despite these important implications, 
the precise roles of the modification are only beginning to be understood. Major challenges 
to the study of O-GlcNAc include its difficulty in detection, substoichiometric presence 
and ubiquitous nature, often modifying multiple sites on the same protein. As a result, 
detailed mechanistic studies have been lacking in the field, and only a few studies have 
established how site-specific glycosylation affects protein function.  With that said, the 
development of chemical approaches to study the site-specific effects of O-GlcNAcylation 
offer a route to overcome these barriers of study. Using these methods to synthesize 
homogeneously glycosylated proteins will be critical to further understanding the role this 
modification plays in protein structure and function.   
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Figure 5.1. Dynamic, covalent attachment and removal of O-GlcNAc is catalyzed by two 
enzymes, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), respectively.  
Protein Modification by O-GlcNAc 
Unlike the 518 kinases and ~200 phosphatases that phosphorylate and 
dephosphorylate different protein substrates, the covalent modification of O-GlcNAc is 
regulated by two enzymes, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) 
(Figure 5.1).13-16 OGT and OGA catalyze the reversible addition and removal of O-GlcNAc 
respectively. How these two enzymes append and remove O-GlcNAc site-specifically on 
particular protein substrates is largely unknown. Activity of these two enzymes is thought 
to be regulated by accessory proteins that potentiate their specificity. For example, the three 
OGT isoforms differ in the number of tetratricopeptide repeats (TPRs) within its N-
terminal domain.17 These TPRs serve as protein-protein interaction modules that have been 
shown to interact with proteins such as the GABAA receptor-associated protein (GRIF-1) 
and its homolog, O-GlcNAc transferase interacting protein (OIP106).18 
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From a functional perspective, O-GlcNAc has been shown to play roles in both 
disrupting5,19,20 and enhancing21-23 protein-protein interactions as well as competing with 
phosphorylation directly.19,24,25 In particular, this has led to interesting studies and 
questions on the interplay between phosphorylation and glycosylation.19,26,27 In these 
studies, a global increase in O-GlcNAcylation was shown to change the stoichiometry of 
almost all presently cycling phosphorylation sites among 711 phosphopeptides. However, 
general analyses the site specific effects and interplay of O-GlcNAc has been severely 
hampered by the difficulty in detection of the modification, chemical and enzymatic 
lability, substoichiometric presence, and complex cellular regulation. The field would 
greatly benefit from the use of techniques to overcome these limitations and dissect the 
functional implications of the modifications.   
 
Cyclic-AMP Response Element Binding Protein (CREB) 
Cyclic-AMP response element binding protein (CREB) is a transcription factor that 
underlies diverse processes, ranging from long-term potentiation and drug addition to 
circadian rhythm. It has been extensively studied in the context of its inducible activity 
through many cellular stimuli, including cyclic-AMP (cAMP) and Ca2+ signaling, leading 
to the attachment of posttranslational modifications. Phosphorylation of Ser133, the most 
well studied regulatory site on the protein, leads to the recruitment of the coactivator 
CREB-binding protein (CBP) and activation of CREB-mediated transcription. However, 
there also exist other mechanisms for CREB-dependent transcription as phosphorylation is 
now always sufficient to stimulate activity. 
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 Work in our lab has shown that O-GlcNAc can serve as another mechanism for 
gene regulation through the modification of CREB.5,28 CREB was found to contain six 
potential sites of glycosylation and each was variably modified. Our data suggested that 
the predominant glycosylation site, Ser40, served as a constant repressor of CREB 
transcriptional activity, lowering basal levels of transcription. In addition to modulating 
constitutive transcription, observed increases in glycosylation after neuronal stimulation 
were proposed to be part of a larger complex signaling mechanism to balance gene 
transcription. In vivo expression of an S40A CREB mutant led to mice with increased 
capacity to form long term memory, Interestingly, on a molecular level, glycosylation at 
Ser40 disrupts the binding of phosphorylation-independent CREB-regulated transcription 
coactivator (CRTC), known to bind to the bZIP domain.29 How a small modification near 
the N-terminus can effect a protein-protein interaction by the C-terminus is unknown, but 
implicates a long-range interaction between the ends of this protein. 
 Structurally, CREB is made up of four domains: two glutamine rich domains (Q1 
and Q2) separated by the kinase inducible domain (KID) and a C-terminal bZIP domain 
(Figure 5.2).30 Each domain serves to facilitate interactions with coactivators and 
components of the transcriptional machinery. Despite the importance of CREB and its 
discovery thirty years ago, the complete structure of the protein has yet to be solved.31 It 
has been hypothesized that the protein is disordered making structural studies challenging. 
Nevertheless, the structure of two of the four domains of CREB have been solved. The 
bZIP domain of CREB bound to a CRE oligonucleotide has been previously crystallized. 
The structure showed the important interactions that allow for CRE specific binding and 
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dimerization between CREB family members.32 Key residues conserved between bZIP 
containing family members such as Arg301 and Lys304 make central interactions with the 
core base pairs that define the CRE sequence. Furthermore, The solution structure of the 
interaction between the CREB KID domain and CBP KIX has been previously solved.33  
This structure elucidated the important interactions between CREB and CBP required for 
phosphorylation-dependent transcription. Phosphorylation at Ser133 of the KID domain 
allows for the formation of a critical hydrogen bond anchor between the phosphate oxygen 
and Tyr658 hydroxyl in the KIX domain. Mutation of Ser133 to alanine abolished their 
interaction in vitro. Importantly, these studies serve as precedence for the induction of 
structural changes following the addition of post-translational modifications on CREB. 
These studies warrant the investigation of how O-GlcNAc may be effecting CREB 
structure and transcriptional activity.   
 
 
 
 
 
 
 
 
 
 
Q1 Q2KID bZIP
1 341
40S 133S 227TT228 259TST261 
O
HOHO
HO
AcHN
O OHOHO
HO
AcHN
O OHOHO
HO
AcHN
O
Figure 5.2. Four domains of CREB and locations of key phosphorylation and O-
GlcNAcylation sites.  CREB is composed of four domains consisting of glutamine rich 
domains (Q1 and Q2), kinase inducible domain (KID), and a basic leucine zipper (bZIP) 
domain. Phosphorylation at Ser133 has been shown to be a key regulatory element in the 
activation of CREB transcription. Six O-GlcNAc modified sites have been identified 
throughout the Q1 and Q2 domains with Ser40 being the predominant site of glycosylation.  
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Structural Implications of O-GlcNAc 
The effects of O-GlcNAc at the protein level are unknown (e.g. steric hindrance, 
creation of a protein-binding surface, conformational change, etc.). Studies on the protein 
level have been hindered by the difficulty in acquiring homogeneous and site-specifically 
glycosylated proteins. However, there exist studies on the peptide level that have provided 
insights into the potential role O-GlcNAc on protein structure.  
Wong and coworkers found that when the threonine residue of the polymeric 
domain of RNA polymerase II, a known site of glycosylation, is O-GlcNAcylated, a turn-
like structure is induced when compared to the random coil unglycosylated peptide.34 In 
another study by Wong and coworkers, the conformational changes of a peptide of the 
mucin domain of MAdCAM-1 were examined by NMR and computational modeling when 
different carbohydrates, including O-GlcNAc, were attached. The NMR data showed that 
the O-GlcNAc peptide was clearly to interact with neighboring sidechains. Upon further 
elaboration with galactose and sialic acid, these noticeable GlcNAc interactions 
disappeared, implying a conformational change.35 Li and coworkers examined similar 
changes by NMR when using the N-terminus peptide of murine estrogen receptor β. 
Attachment of an O-GlcNAc moiety created a higher degree of the type II β-turn-like 
structure in the region. Interestingly, adding a phosphorylation at the same Ser16 residue 
induced a more extended structure.36  
While these studies implicate the potential for O-GlcNAc to induce structural 
change, they model the change on short peptides and do not exclude other mechanisms of 
by which O-GlcNAc can effect function. Expansion of such analyses to proteins will be 
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essential to understand the effects of O-GlcNAcylation on protein structure and dynamics, 
including its potential to modulate long-range interactions. 
 
Methods for the Semi-Synthesis of O-GlcNAcylated Proteins 
Use of chemical approaches presents one of the few avenues in which the structural 
effects of site-specific glycosylation can be studied. There exists a limited amount of 
techniques to generate homogeneously glycosylated protein. The two principal methods 
for achieving this are expressed protein ligation and bioconjugation of an introduced 
dehydroalanine (Dha). These methods have given researchers great insights into the 
functional roles these proteins play, but have yet to bear any structural information.  
Expressed protein ligation has proven to be a powerful tool in the generation of 
semi-synthetic proteins.37-39 This approach utilizes the unique reactivity of a 
protein/peptide fragment containing an N-terminal cysteine with another protein/peptide 
fragment containing a C-terminal thioester. The method can be applied universally to 
almost any protein containing cysteines or tolerant of the introduction of cysteines. There 
also exist methods of radical desulfurization to convert cysteine to alanine, expanding the 
scope of this method.40 The limitations of this method derives from limiting the number of 
ligations as protein yield and purity decrease with increasing ligations. In the context of O-
GlcNAc, there are two examples in which this form of semisynthesis has been used to 
elucidate the biological implications of O-GlcNAc. Cole and coworkers used a one-step 
ligation to study the effects of O-GlcNAcylation and phosphorylation on casein kinase 2 
(CK2). They determined that phosphorylation at Thr344 and glycosylation at Ser347 
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played critical roles in determining the substrate specificity of CK2.41 In another example, 
Pratt and coworkers utilized a two-step ligation to generate α-synuclein O-GlcNAcylated 
at Thr72. The functional consequence of this modification was determined to be an increase 
in solubility and decrease in the number of aggregates that are usually related to 
neurodegeneration.42  
 The method developed by Davis and coworkers is based on the facile alkylation 
and elimination of a cysteine sidechain to Dha.43-46 The reaction has been accomplished by 
the development of two reagents: O-mesitylenesulfonylhydroxylamine (MSH) and 2,5-
dibromohexanediamide (DBHDA). This transformation provides an electrophilic handle 
for the nucleophilic addition of different kinds of thiol-containing post-translation 
modification analogs (Figure 5.3). This method has been successfully demonstrated for the 
attachment of phosphorylation, glycosylation, acetylation, and methylation mimics. 
Despite the likeliness of forming Cα epimers at the amino acid of interest, the proteins that 
have been semi-synthesized through this approach have been functionally active.43-46 Using 
this method, Davis and coworkers were able to show that these mimics were recognized 
by antibodies developed for the natural modifications, as well as successful deacetylation 
of the aceytllysine mimic by histone deacetylase (HDAC) 1 and HDAC2.44 They also used 
this method to support the hypothesis that O-GlcNAc glycosylation of histone H2A at 
Thr101 disrupts nucleosome formation and increases transcriptional activity by lowering 
the barrier of RNA polymerase passage.46 The largest limitation for this method is that it 
requires other cysteine residues to be mutated to their serine counterparts. If the protein 
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cannot tolerate this change (i.e. disulfide bridges, catalytic cysteines, etc.) then the method 
is most likely not amenable.   
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C h a p t e r  6  
EXAMINING THE ROLE OF O-GLCNAC ON CREB THORUGH 
SEMISYNTHESIS 
Introduction 
The β-N-acetyl-D-glucosamine (O-GlcNAc) post-translational modification plays a 
major role in many diseases such as cancer,1-4 diabetes,4-6 and neurodegenerative disorders,7-
9 but much is still unknown about its molecular-level influence on protein structure and 
function. Although post-translational modifications have been known to impart structural 
changes leading to functional outcomes, notably, no structures of O-GlcNAcylated proteins 
exist. The challenge of obtaining homogeneous glycoproteins bearing the GlcNAc sugar at 
defined sites has hindered the biophysical studies of how this modification can affect 
structure on the protein level. Here we have utilized a semisynthetic approach to generate a 
homogeneously O-GlcNAcylated form of cyclic-AMP response element binding protein 
(CREB) for structural and functional studies. 
 
Results and Discussion 
To site-specifically study the role of O-GlcNAc in protein structure and function, we 
would need the homogeneously glycosylated protein of interest. For the protein of interest, 
we chose to investigate the role of O-GlcNAc on CREB because of our established interest 
in the modification’s ability to repress long-term potentiation and memory formation through 
this transcription factor.10,11 To generate a homogenous population of glycosylated CREB, 
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we opted to use the established chemical glycosylation approach developed by Davis and 
coworkers that utilizes the conversion of a cysteine sidechain to an electrophilic 
dehydroalanine (Dha).12-14 This olefin sidechain can then serve as a point of nucleophilic 
attachment for a thiol-containing GlcNAc analog. An intrinsic limitation to this method is 
that it cannot be used on proteins containing native cysteine residues that are critical for 
protein structure and function. While CREB contains four native cysteine residues, three 
(C300, C310, C337) exist in the bZIP domain and have been previously mutated out with no 
effect on its ability to be crystallized bound to the CRE consensus sequence.15 We reasoned 
that since the last cysteine residue (C90) was not involved in disulfide bond formation, 
mutation to serine would be nonperturbing.  
The most critical component for these studies was to express and purify this mutant 
form of CREB to homogeneity. Using site directed 
mutagenesis, we designed our construct to contain 
S40C, C90S, C300S, C310S, and C337S mutations. 
This allowed for bioconjugation to occur only at the 
amino acid site of interest (S40). The expression and 
handling of CREB has been plagued by poor stability, 
co-purification with DNA, and dimerization with 
truncation products; all of which would present issues 
for potential structural studies. To generate the 
homogenous protein, we adapted a previously reported 
purification protocol that utilized denaturing and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Mutant CREB was 
purified to >95% homogeneity 
through denaturing protocol as 
analyzed by Coomassie 
staining (lane 2). 
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refolding conditions to easily remove bound DNA and truncation products.16 In short, this 
method included heat extraction from lysate, denaturing nickel-affinity chromatography, 
hexahistidine-tag cleavage, protein refolding, and size exclusion chromatography (SEC) 
steps. Following these steps, we were able to obtain a protein of greater than 95% 
homogeneity (Figure 6.1). Interestingly, we observed that our mutant was stable for months 
at 4°C as opposed to the wild type protein, most likely a result of oxidation and aggregation 
of the free cysteine residues.17  
To functionally verify that these procedures produced a refolded and biologically 
relevant protein, we tested its ability to bind the CRE consensus sequence and elicit a 
transcriptional response. DNA binding was assessed by electrophoretic mobility shift assay 
(EMSA) with an infrared-labeled CRE consensus sequence oligonucleotide. The binding of 
this mutant was confirmed and showed sequence selectivity as binding competed with an 
oligonucleotide bearing an identical sequence without the reporter (Figure 6.2A). To gauge 
if this purification process generated a transcriptionally active protein, an in vitro 
transcription assay, employing HeLa cell lysates, was used to detect activity.  Natively 
expressed CREB, without denaturing purification, expectedly did not produce 
transcriptionally active CREB, most likely a result of being tightly bound to DNA. When 
purified under denaturing conditions, the mutant was unexpectedly 8-fold less active as 
compared to wild type CREB (Figure 6.2B). This decrease in activity, but not DNA binding, 
may be a result of diminished binding to the CRTC transcriptional cofactor as demonstrated 
with a similar triple mutant.18 Indeed, it was shown that the existence of C310 positively 
affects and C300 negatively regulates CREB-CRTC binding. However, we posited that as 
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long as there was sufficient signal to detect activity, we can still infer the effects of O-
GlcNAcylation on CREB using this expressed form of the protein.  
 
 
 
 
 
 
 
 
 
 
With the protein in hand, we sought to conjugate it to a GlcNAc analog. To achieve 
this, we synthesized the previously reported O-mesitylenesulfonylhydroxylamine (MSH) 
and 2,5-dibromohexanediamide (DBHDA) reagents in two steps each and have been 
previously reported to convert cysteine to Dha.12,19 The S-GlcNAc analog, 1-thio-2-
acetamido-2-deoxy-β-D-glucopyranose was also synthesized in three steps to for the final 
conjugation step.13  
We next optimized the conditions for the two-step conversion of CREB to S-
GlcNAcylated CREB (Figure 6.3), by varying parameters such as the equivalents of the 
alkylating agent, protein concentration, reaction temperature, and time. Unexpectedly, we 
were unable to reproduce the ability of MSH to convert cysteine to Dha and thus moved on  
Mut. CREB         -          +          +          +        
Com. Oligo.        -           -       10 eq.      -   
Scram. Oligo.      -           -          -       10 eq.   
WT CREB               -            +              +             -             -    
Mut. CREB              -            -               -             +            + 
Nat. Purif.                -            +              -              +            - 
Denat. Purif.             -            -               +             -            + 
Figure 6.2. Expressed WT and mutant CREB were evaluated for their ability to bind DNA 
and lead to transcriptional activity. (A) The mutant CREB construct specifically bound to the 
CRE consensus sequence as analyzed by EMSA. Mut: mutant; Com: complementary; Scram: 
scramble; Oligo: oligonucleotide. (B) CREB purified natively showed no transcriptional 
activity. When purified under denaturing conditions, the mutant form was 8-fold less active in 
transcribing linearized DNA as compared to the WT protein. WT: wild type; Mut: mutant; 
Nat: native; Denat: denaturing; Purif: purification.  
A B
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Table 6.1. Cys to S-GlcNAc Conversion with DBHDA. 
Reaction Conditions  
 
Product 
Mass 
Detecteda 
 
 
Protein 
Conc. 
(mg/mL) 
 
DBHDA 
Equiv. 
Dha 
Incubation #1 
Dha 
Incubation #2 
S-GlcNAc 
Incubation 
 
Purityb 
Time 
(min)
Temp. 
(°C) 
Time 
(min)
Temp.
(°C) 
Time 
(min)
Temp. 
(°C) 
(%) 
1 770 30 RT - - - - No - 
1 770 30 RT 60 37 - - No - 
1 770 30 RT 90 37 - - Yes 27 
1 770 30 RT 120 37 - - Yes 16 
1 770 30 RT 18 h RT - - No - 
1 770 30 RT 18 h 4 - - No - 
1 10 30 RT 90 37 - - No - 
1 50 30 RT 90 37 - - No - 
1 100 30 RT 90 37 - - Yes 72 
1 250 30 RT 90 37 - - Yes 73 
1 100 15 37 - - - - No - 
1 100 30 37 - - - - No - 
1 100 60 37 - - - - No - 
1 100 90 37 - - - - Yes 33 
2 100 30 RT 90 37 - - Yes 76 
4 100 30 RT 90 37 - - Yes 77 
1 770 30 RT 90 37 90 RT Yes 26 
1 100 30 RT 90 37 180 RT Yes 44 
1 100 30 RT 90 37 18 h 4 No - 
2 100 30 RT 90 37 120 37 Yes 82 
2 100 30 RT 90 37 18 h RT Yes 75 
2 100 30 RT 90 37 18 h 37 No - 
aCalculated Dha-containing CREB: 36607, GlcNAc-containing CREB: 36844. n.d.: not detected. 
bFinal purity was normalized to starting CREB purity after evaluation of LC-MS abundances 
 
Figure 6.3. One-pot chemical glycosylation reaction of CREB. Under slightly basic, buffering 
conditions, cysteine sidechains can be alkylated and eliminated with the addition of 2,5-
dibromohexanediamide (DBHDA). The following excess addition of a thiol-containing 
GlcNAc analog led to the generation of homogeneously glycosylated CREB.   
50 mM NaPi pH 8.0 50 mM NaPi pH 8.0
CREBCREBCREB 
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with the use of DBHDA. After initial reactions of CREB with DBHDA, we realized 
optimization of this first step was critical because of the observed likeliness to form many 
side products. To minimize these side products, iterative fine-tuning of these reaction 
conditions was performed and S40C CREB reacted with DBHDA (100 eq.) in pH 8.0 
phosphate buffer for 30 min at room temperature then 37 °C for 1.5 h led to complete 
conversion to the corresponding Dha40 CREB, as the starting protein was no longer detected 
when analyzed by LC-MS (Table 6.1). Subsequent addition and incubation with S-GlcNAc 
(5000 eq.) for 2 h at 37 °C produced the desired S-GlcNAcylated product at a final purity of 
82%, as evaluated by SDS-PAGE and LC-MS. (Figure 6.4). Importantly again, the Dha-
containing protein mass was undetectable, indicating complete conversion after each step. 
Further verification of the reaction was performed through collision-induced 
dissociation mass spectrometry (CID-MS) and purification by wheat germ agglutinin (WGA) 
affinity chromatography to enrich for GlcNAcylated CREB. In-gel trypsin digestion, 
followed by tandem MS, allowed us to confirm the presence of Dha and S-GlcNAc at the 
S40C position (Figure 6.5). The semi-synthetic protein was also specifically bound and 
eluted from solid support bound WGA, a lectin with a specific affinity for the GlcNAc 
moiety, indicating the presence of the chemical modification (Figure 6.6). It is important to 
note that the posttranslational modification mimics introduced by this method are likely 
formed as Cα epimeric mixtures. Nevertheless, despite this isomerism, these mimics have 
been shown to be functional in both immunoblot and enzymatic assays.14,19,20 Thus, it was 
still expected to generate functionally active proteins.    
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Figure 6.4. Intact protein LC-MS showed the rapid conversion of (A) mutant CREB to (B) 
Dha-containing CREB and to (C) S-GlcNAc-containing CREB. Mass shifts of -35 m/z and 
+205 m/z corresponded to the elimination of cysteine (Dha) and addition of S-GlcNAc, 
respectively. Full ion chromatogram (left) led to the expected deconvoluted (right) mass 
within error of the method. Deconvoluted mass spectra were analyzed with a 15% abundance 
cutoff with a minimum of 12 set peaks.    
A 
B 
C 
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A 
B 
Figure 6.5. CID-MS analysis of in-gel chymotryptic digests after bioconjugation reactions 
identified CREB peptides bearing Dha and S-GlcNAc at S40C position. (A) Peptide 
containing Dha on S40C position after alkylation and elimination reaction. (B) Peptide 
fragments containing unique modified (green) and unmodified (blue) masses identified S-
GlcNAc at S40C. Peptide fragments that are part of both modified and unmodified peptides 
are in black. 
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To determine the integrity of the protein post-reaction, we assessed the ability of the 
protein to bind DNA. In cellular studies, we previously showed that CREB bearing a S40A 
mutation bound to the CRE consensus sequence with equal affinity as compared to the wild 
type.11 Using EMSA, we surprisingly first observed no DNA binding by the reacted Dha and 
S-GlcNAc-containing proteins. However, upon further investigation, we determined that 
these reaction conditions denatured the protein. Despite being reported as a reaction under 
native conditions, protein denaturation is likely protein dependent. Fortunately, the refolding 
conditions for CREB are known and after refolding, all CREB variants displayed equal DNA 
binding affinities (Figure 6.7). These findings re-confirm that O-GlcNAcylation must disrupt 
the interaction of a cofactor protein opposed to directly affecting DNA binding.    
 
250 
150 
 
100 
75 
 
 
50 
37 
 
25 
20 
15 
10 
 
250 
150Figure 6.6. Wheat germ agglutinin (WGA) purification of semisynthetic CREB. WGA-bound 
agarose is able to recognize and specifically bind S-GlcNAcylated CREB as indicated by 
Coomassie staining. Minimal presence in the flowthrough and specific elution of CREB by 
GlcNAc support the success of the semisynthetic route.  
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Conclusion 
In conclusion, here we have generated CREB site-specifically glycosylated at Ser40 
with an S-GlcNAc analog and demonstrated the potential of using the proposed strategy for 
the synthesis of O-GlcNAcylated proteins. Chemical glycosylation was achieved through the 
unique conversion of a cysteine residue to Dha, followed by the nucleophilic addition of a 
thiol-containing GlcNAc analog. Reaction optimization and progress were monitored by LC-
MS and indicated the complete conversion to the glycosylated product. Finally, the 
generation of functional protein was verified by the recapitulation of the DNA binding effects 
seen in a native cellular context.  
The generation of homogeneously glycosylated CREB will allow for future 
experiments to further understand the structural and functional implications of this 
modification. Access to the glycosylated form will allow for functional studies into the 
Figure 6.7. CREB DNA binding was unaffected by S40C modification as detected by 
electrophoretic mobility shift assay (EMSA). Both Dha-modified and S-GlcNAc-modified 
CREB did not show any significant change in DNA binding as compared to unmodified CREB 
indicating that modification at this position does not affect the DNA binding domain 
reconfirming findings from previous cellular studies.  
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interplay between glycosylation and phosphorylation at the molecular level. The results 
should provide insights into potential combinatorial effects within the same protein molecule 
– a phenomenon that cannot be readily studied in cells. Moreover, with this method, we can 
also begin to dissect the functional roles of the six different glycosylation sites within CREB 
be generating each glycoprotein and evaluating their effects on protein interactions and 
transcriptional activity.  
Studies have suggested long-range interactions between the Q2 and KID domains of 
CREB.21 Moreover, we found that glycosylation at Ser40 disrupts CREB’s interaction with 
CRTC. Coupled with the observation that CRTC interacts primarily with the bZIP domain 
of CREB, this is indicative of potential long-range interactions. These findings, combined 
with the potential of O-GlcNAc modifications to induce structural change, make O-GlcNAc 
induced structural change in CREB one potential mechanism.  Potential future work on 
elucidating the structural implications would include protein crystallization of the 
glycosylated protein or NMR studies of specific CREB domains.   
 
Experimental Methods 
Mutagenesis. Protocols were followed directly from Agilent QuikChange Lightning 
Mutagenesis Kit. Rat CREB in a pET23b vector was donated by Richard Goodman 
(OHSU). In short, primers were designed via Agilent website for each mutation separately. 
The provided reaction buffer and reagents were incubated with primers (IDT) and template 
vector and subjected to the recommended PCR conditions. The PCR product was digested 
with the provided DpnI and transformed into XL10-Gold ultracompetent cells.  
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CREB Bacterial Expression and Purification. Rat CREB was expressed as construct 
containing an N-terminally His6-tag and TEV cleavage site in a pET23b vector. Expression 
was carried out in Rosetta 2 (DE3) pLysS cells. Transformed cells were grown at 37°C in 
1L LB medium supplemented with 100 ug/mL ampicillin and 34 ug/mL chloramphenicol. 
At OD600 = 0.8, cells were induced with the final concentration of 0.4 mM IPTG and left 
to shake an additional 3 hours at 37°C. Cells were pelleted at 4000 rpm at 4°C for 30 min 
and stored at -80°C until purification. The cells were resuspended in resuspension buffer 
(50 mM Tris pH 7.9, 100 mM KCl, 12.5 mM MgCl2) and final concentrations of 25 ug/mL 
RNAse, 2 mM dithiothreitol (DTT), 1x EDTA-free protease inhibitor cocktail, and 1 mM 
PMSF. The mixture was aliquoted into 1.5 mL centrifuge tubes and heated on a heating 
block at 65°C for 15 mins. Immediately after, the aliquots were put on ice for 10 mins and 
2 mM DTT, 1x EDTA-free protease inhibitor cocktail (Roche), and 1 mM PMSF were 
added again. Cells were spun down at 13,000 rpm for 30 mins at 4°C. The soluble fraction 
was then added to 3 mL of pre-equilibrated Ni-NTA agarose and incubated for 1 hour at 
4°C with end to end rotation. The resin was washed with 90 mL of washing buffer (10 mM 
Tris, 100 mM NaH2PO4, 8 M urea, pH 6.3) at RT. Protein was eluted with elution buffer 
(10 mM Tris, 100 mM NaH2PO4, 8 M urea, pH 5.9). The protein was then buffer exchanged 
into 100 mM Tris pH 8.0 with 30 kDa MWCO spin filters and incubated with His6-TEV 
protease (0.5 mg/mL) in a 1:50 TEV:protein ratio for 1 h at RT. The mixture was then 
flowed over pre-equilibrated Ni-NTA agarose and the flowthrough was collected. The 
purified protein was then refolded by dialysis 3 times in 4 L of dialysis buffer (50 mM 
NaH2PO4  pH 8, 100 mM NaCl, 1 mM MgCl2, 2 mM DTT).  
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Electrophoretic Mobility Shift Assay (EMSA). In a 20 uL reaction, 1 ug of CREB was 
incubated in a buffer containing a 20x EMSA buffer (200 mM Tris pH 7.5, 3 M KCl, 200 
mM DTT, 5 mM EDTA), 0.1 ug/uL poly(dIdC), 2% glycerol, and 1 uL of CREB IRDye 
700 (LICOR) at RT for 30 mins. The reaction was then separated on a 12% polyacrylamide 
gel in TAE buffer (40 mM Tris, 2.5 mM EDTA, pH to 7.8 with acetic acid) for 2.5 hours. 
Gels were imaged on an Odyssey Imager (LICOR). 
 
In Vitro Transcription Assay. Assays were performed using HeLaScribe Nuclear Extract 
(Promega) according to the manufacturer’s protocol with minor modifications. Linearized 
CRE template DNA was prepared by digesting the plasmid pCRE-Luc (Stratagene) with 
NdeI and EcoRV. The resulting 2.1 kb fragment containing the CRE enhancer and partial 
luciferase ORF (~1.4 kb) was gel purified. Recombinantly expressed CREB (0.225 µg) 
was combined with the CRE template DNA (100 ng), 0.4 mM rATP, 0.4 mM rUTP, 0.4 
mM rCTP, 0.016 mM rGTP and 10 µCi [α-32P]rGTP (3000 Ci/mmol) in 7.3 mM HEPES 
pH 7.9, 6.1 mM MgCl2, 37 mM KCl, 0.07 mM EDTA, 0.2 mM DTT, 5.5% glycerol. 
Transcription reactiosn were initiated by the addition of HeLaScribe nuclear extract (8 U). 
Run-off RNA transcripts were resolved on 7 M urea 6% TBE-PAGE gels and visualized 
by autoradiography using the Typhoon FLA 7000.  
 
Bioconjugation Reaction of Cys  Dha  S-GlcNAc. Recombinantly-expressed, 
mutant CREB was buffer exchanged and concentrated to 2 mg/mL using 3 kDa MWCO 
spin filters (Millipore) into a 50 mM NaH2PO4 pH 8.0 at 4 °C. MSH (14 mg/mL) or 
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DBHDA (132 mg/mL) in DMF was added at the appropriate equivalence to the protein 
solution and quickly mixed by pipetting. MSH reactions were carried out at 4 °C for 20 
min with end-over-end rotation. DBHDA reactions were first incubated at RT for 30 min 
then moved to 37 °C for 90 min with end-over-end rotation. After the indicated times, an 
aliquot was removed for later analysis by LC-MS to confirm the conversion to Dha. Solid 
1-thio-2-acetamido-2-deoxy-β -D-glucopyranose was then added to the solution (5000 eq.) 
and the reaction was incubated at 37 °C for 2 h with end-over-end rotation. After 2 h, the 
reaction was quenched by dilution with 10 mM Tris, 100 mM NaH2PO4, 8 M urea, pH 6.3 
and refolded by dialysis 3 times in 4 L of dialysis buffer (50 mM NaH2PO4  pH 8, 100 mM 
NaCl, 1 mM MgCl2, 2 mM DTT) with 12 kDa MWCO dialysis tubing. The final protein 
was then analyzed by LC-MS and SDS-PAGE for reaction completion and purity.   
 
Intact Protein Mass Spectrometry. Liquid chromatography-mass spectrometry (LC-MS) 
was performed on an Agilent 1100 Series HPLC coupled to an Agilent 1100 Series MSD 
connected to an Agilent Zorbax 300SB-C3 (Narrowbore 2.1x150mm, 5um) column. The 
sample was buffer exchanged into 2% formic acid with 3 kDa MWCO spin filters and 
injected and subjected to 25 min of 0.2% formic acid in water to desalt. Then a linear 
gradient was applied for 25 min to 95% acetonitrile with 0.2% formic acid and 10% 
methanol. All of this was performed at a flow rate of 0.2 mL/min. After the run, the column 
was equilibrated for 10 min with solvent A. The electrospray source had a capillary voltage 
of 4.0 kV. Nitrogen was used as the nebulizer and desolvation gas with a flow rate of 3 
L/min. Protein will typically elute between 38 and 46 min. ChemStation from Agilent was 
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used to analyze and deconvolute mass ion data. The system was calibrated with Agilent 
ESI Tuning Mix and accuracy was confirmed with a standard sample of apomyoglobin. 
Protein purity was determined by the ratio of product ion abundance versus the abundance 
of the total protein ions found with a 5% protein abundance cutoff.  
 
Peptide Identification by LC-MS/MS. A directed mass spectrometric search was used to 
determine the positions of Dha and S-GlcNAc labeled peptides. Semi-synthetically 
prepared CREB was analyzed by SDS-PAGE (4-12% Bis-Tris gels) and the resulting bands 
were cut out. In-gel digestion of gel bands with chymotrypsin was performed as previously 
described.22 To help identify peptides corresponding to Dha and S-GlcNAc modifications, 
an m/z inclusion list for expected peptide ions was generated. LC-MS/MS experiments 
were performed on an LTQ-FT Ultra mass spectrometer (Thermo Fisher Scientific) 
equipped with a nanoelectrospray ion source (Thermo Fisher Scientific) connected to an 
EASY-nLC II (Thermo Fisher Scientific). MS/MS spectra were collected in CID mode and 
target MS/MS were searched using the ROCCIT MS/MS Search Engine.  
 
Wheat Germ Agglutinin (WGA) Affinity Purification. Protocol was followed from 
Curr. Protoc. Protein Sci. 2011, Chapter 12, Unit 12.8.23 In short, semi-synthetically 
prepared CREB was incubated end-over-end with WGA-agarose (Vector Labs) pre-
equilibrated with 10 mM phosphate buffer pH 7.8, 150 mM NaCl (Washing Buffer) for 30 
min at 4 °C. After 30 min, the beads were applied to a column and washed with 4 column 
volumes of Washing Buffer and 4 column volumes of 10 mM phosphate buffer pH 7.8, 
125 
 
150 mM NaCl, 1 M D-galactose (Gal Buffer). CREB was then eluted with 7 column 
volumes of 10 mM phosphate buffer pH 7.8, 150 mM NaCl, 1 M D-N-acetylglucosamine 
(GlcNAc Elution Buffer). Fractions were collected and analyzed by SDS-PAGE. 
 
General Methods for Chemical Synthesis. All reactions were carried out under an argon 
atmosphere unless otherwise specified. Reagents were purchased from Sigma Aldrich and 
used without purification unless otherwise specified. 1H NMR spectra were recorded with 
a Varian Inova 500 (500 MHz) and are reported relative to residual solvent peaks. Data for 
1H NMR are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant 
(Hz), integration, assignment). Multiplicities are reported as follows: s = singlet, d = 
doublet, t = triplet, m = multiplet, br = broad. Data for 13C NMR are reported in terms of 
chemical shifts (δ ppm). 
 
Synthesis of ethyl-O-(mesitylenesulfonyl)acetohydroxamate. 3.5 g (34.0 mmol) of ethyl 
N-hydroxyacetimidate (Alfa Aesar) was dissolved into 9 mL of DMF. 4.5 mL of triethylamine 
(Alfa Aesar) was added and the solution was stirred at 0°C fir 15 mins. 7.5 g (34.3 mmol) of 2-
mesitylenesulfonyl chloride (TCI America) was added in two portions and stirred vigorously for 
30 mins at 0°C. Mixture took on an orange sticky consistency. Mixture was diluted with DCM and 
extracted with H2O to remove DMF. The organic layer was dried with MgSO4, filtered, and solvent 
removed under reduced vacuum. The final product was used without further purification as a white 
solid in 83% yield. 1H NMR (500 MHz, CDCl3) 1.20 (3H, t, J = 7.1 Hz, CH2CH3), 2.04 (3H, s, 
CH3), 2.31 (3H, s, CH3Ar), 2.64 (6H, s, 2 x CH3Ar), 3.90 (2H, q, J = 7.1 Hz, CH2CH3), 6.97 (2H, 
s, Ar-H). 
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Synthesis of O-mesitylenesulfonylhydroxylamine (MSH). Caution, MSH can detonate 
if crystallized improperly. 7.1 g (24.8 mmol) of 1 was added to 6.4 mL of p-dioxane and 
stirred at 0°C for 20 min. 2.9 mL of 70% perchloric acid (Sigma) was added slowly 
dropwise via pipette over 2 min and maintaining the temperature under 10°C. After 10 min 
of stirring at 0°C, the mixture solidified. The mixture was then transferred to a 1 L 
Erlenmeyer flask with 320 mL of ice water and rinsed with water and ethyl ether. The 
contents were then extracted with more ethyl ether. The organic layer was neutralized with 
potassium carbonate for 5 min and filtered. The filtrate was then concentrated to less than 
160 mL and poured into 240 mL of ice cold hexanes. Crystallization was allowed to 
proceed overnight at 4°C. Small white needles were crystallized, filtered, and transferred 
to a plastic Falcon tube. The compound was further dried under vacuum and stored at -
20°C at 41% yield. 1H NMR (500 MHz, CDCl3) 2.33 (3H, s, CH3Ar), 2.65 (6H, s, 2 x 
CH3Ar), 3.85 (2H, br, NH2), 7.00 (2H, s, Ar-H). MS-TOF: [M+H]+ 216.2515. 
 
Synthesis of 2,5-dibromohexanediamide (DBHDA). Adipic acid (5.01 g, 34.3 mmol) 
was added to a 100 mL round bottom flask and suspended in thionyl chloride (15 mL, 207 
mmol). The mixture was refluxed for 1.5 h while stirring open to air at 80 °C. After 1.5 h, 
the reaction was cooled to RT. CCl4 (20 mL) was added to the reaction followed by N-
bromosuccinimide (14.62 g, 82.2 mmol). The reaction was stirred vigorously and 2 drops 
of HBr was added by pipette. The reaction was refluxed again open to air at 85 °C for 2 h. 
After 2 h, the reaction was cooled to RT and then 0 °C. The mixture was stirred at 0 °C to 
ensure the precipitation of succinimide. The solid was removed by filtration and rinsed 
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with Et2O. The filtrate was concentrated in vacuo to yield a thick black liquid. In a separate 
100 mL round bottom flask, 40 mL of NH4OH (28-30% aqueous) was cooled to 0 °C. The 
crude acid chloride was added dropwise to the flask over 20 minutes. After the addition is 
complete, stirring continued for 1 h. The green solid was vacuum filtered and collected. 
The product was purified by triturating in 20 mL of 1:1 MeOH/H2O and heated to 60 °C. 
After cooling to RT, the white solid was collected by vacuum filtration, rinsed with MeOH, 
and dried under vacuum (5.21 g, 50%). 1H NMR (500 MHz, DMSO-d6) 1.78-2.07 (4H, m, 
CH2CH2), 4.29-4.34 (2H, m, 2 x CHBr), 7.31, (2H, s, NH2), 7.69 (2H, s, NH2).    
 
Synthesis of (3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-β-Dglucopyranosyl)-1-
isothiouronium chloride. 4.0 g (TCI America, 10.9 mmol) of 3,4,6-tri-O-acetyl-2-acetamido-
2-deoxy-α-D-glucopyranosoyl chloride and 1.6 g (21.0 mmol) thiourea were dissolved into 34 mL 
of anhydrous acetone. The mixture was refluxed under argon for 2 hours at 60°C. The precipitate 
that built up was removed and the mixture was returned to reflux until there was no more 
precipitation. The white solid was then rinsed with acetone and hexanes, filtered, and dried under 
vacuum for an 89% yield. 1H NMR (500 MHz, DMSO-d6) 1.81 (3H, s, NHCOCH3), 1.95 (3H, s, 
CH3), 1.99 (3H, s, CH3), 2.02 (3H, s, CH3), 4.06 (1H, dd, J5,6 = 2.2 Hz, J6,6’ = 10.0 Hz, H-6), 4.17 
(1H, dd, J5,6’ = 5.0 Hz, J6,6’ = 12.3 Hz, H-6’), 4.26 (1H, ddd, J4,5 = 10.2 Hz, J5,6 = 2.3 Hz, J5,6’ = 4.7 
Hz, H-5), 4.94 (1H, at, J 9.8 Hz, H-4), 5.13 (1H, at, J 9.7 Hz, H-3), 5.63 (1H, d, J1,2 10.3 Hz, H-
1), 8.40 (1H, d, J 9.3 Hz, NHAc), 9.20 (4H, brs, 2 x NH2). 
 
Synthesis of 1-thio-3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-β-D-glucopyranose. 4.2 g 
(9.51 mmol) of (3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-β-D-glucopyranosyl)-1-
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isothiouronium chloride was dissolved in DCM and H2O by stirring at RT. 2.2 g (11.6 
mmol) of sodium metabisulfite was then added to the mixture and refluxed at 46°C for 2 
hours. The reaction was left to cool to RT after 2 hours. The mixture was then extracted 
twice with DCM. All organic layers were combined and washed with H2O and brine and 
dried over MgSO4. The solvent was removed by under reduced vacuum and recrystallized 
in hot EtOAc and hexanes. The white solid was filtered and dried under vacuum to a yield 
of 79% yield. 1H NMR (500 MHz, CDCl3) 1.99 (3H, s, CH3), 2.03 (3H, s, CH3), 2.05 (3H, 
s, CH3), 2.10 (3H, s, CH3), 2.57 (1H, d, J1,SH = 9.4 Hz, SH), 3.68 (1H, ddd, J4,5 = 9.8 Hz, 
J5,6 = 4.8 Hz, J5,6’ = 2.2 Hz, H-5), 4.10-4.16 (2H, m, H-2, H-3), 4.24 (1H, dd, J5,6 = 4.8 Hz, 
J6,6’ = 12.5 Hz, H-6), 4.56 (1H, t, J = 10.3 Hz, H-1), 5.05-5.15 (2H, m, H-4, H-6’), 5.55 
(1H, d, J = 9.4 Hz, NH).  
 
Synthesis of 1-thio-2-acetamido-2-deoxy-β -D-glucopyranose. 2.3 g (6.33 mmol) of 3,4,6-
tri-O-acetyl-2-acetamido-2-deoxy-β-D-glucopyranosyl thiol was stirred into MeOH at RT. 1.1 
equivalence of NaOMe (Sigma) was added and the mixture was stirred and monitored for 2.5 hours 
by TLC (40% MeOH/DCM). The reaction was neutralized with Dowex-50 ion exchange resin 
(Alfa Aesar). The mixture was filtered and concentrated under reduced vacuum. The product was 
recrystallized in MeOH/EtOAc to a sticky oil in 40% yield. 1H NMR (500 MHz, MeOH), 2.00 (3H, 
s, CH3), 3.38-3.45 (2H, m, H-4, H-5), 3.52 (1H, t, J = 8.9 Hz, H-3), 3.77-3.82 (2H, m, H-2, H-6), 
3.89 (1H, dd, J5,6’ = 2.2 Hz, J6,6’ = 11.9 Hz, H-6’), 4.74 (1H, d, J1,2 = 10.4 Hz, H-1). MS-TOF: [M-
H]- 236.0628. 
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A p p e n d i x  A  
SYNTHESIS OF URIDINE DIPHOSPHATE 6-AZIDO D-GALACTOSE 
Experimental Methods 
Compound was prepared as previously reported in Tetrahedron Lett. 2008, 49, 2294 with 
some modifications. 
 
General Methods. All reactions were carried out under an argon atmosphere unless 
otherwise specified. Reagents were purchased from Sigma Aldrich and used without 
purification unless otherwise specified. 1H NMR spectra were recorded with a Varian Inova 
500 (500 MHz) and are reported relative to residual solvent peaks. 31P NMR spectra was 
recorded with a Varian Inova 300 (300 MHz). Data for 1H NMR are reported as follows: 
chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration, assignment). 
Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, m = multiplet, br 
= broad. Data for 13C NMR are reported in terms of chemical shifts (δ ppm). 
 
Synthesis of 1,2,3,4-di-O-isopropylidene-6-azido-6-deoxy-α-D-galactopyranose 
1,2:3,4-Di-O-isopropylidene-α-D-galactopyranose (4.5 g, 17.3 mmol) and 4-
dimethylaminopridine (DMAP, 4.22 g, 2 eq) was dissolved into DCM (82 mL) and stirred 
at 0 °C under argon. Methanesulfonyl chloride (MsCl, 2.0 mL 1.5 eq) was added dropwise. 
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The reaction was allowed to stir for 15 min at 0 °C, then warmed to RT and stirred for 1 h. 
After 1 h, the reaction was diluted with DCM (82 mL), filtered through celite, and washed 
with DCM (82 mL). The filtrate was concentrated and dissolved into DMF (82 mL). 
Tetrabutylammonium bromide (5.56 g, 1 eq) and sodium azide (10.2 g. 9 eq) were 
successively added to the reaction mixture and was warmed to 110 °C under argon. After 
5 days, the reaction mixture was cooled to room temperature and concentrated in vacuo. 
Saturated NaHCO3 (164 mL) and DCM (164 mL) were added to the crude compound and 
aqueous phase was extracted with DCM. The organic phase was then washed with water 
(164 mL), brine (328 mL), dried over MgSO4, and concentrated in vacuo. Purification of 
the residue by flash chromatography (9:1 Hex/EtOAc) afforded the compound (4.04 g, 
82%). 1H NMR (500 MHz, CDCl3) δ 1.3 (6H, s, CCH3), 1.42 (3H, s, CCH3), 1.51 (3H, s, 
CCH3), 3.29 (1H, dd, H-6’), 3.44 (1H, dd, J6,6’ = 12.7 Hz, H-6), 3.88 (1H, ddd, J5,6 = 7.7 
Hz, J5,6’ = 5.4 Hz , H-5), 4.14 (1H, dd, J4,5 = 1.9 Hz, H-4), 4.57 (1H, dd, J2,3 = 2.5 Hz, J3,4 
= 2.5 Hz, H-3), 5.50 (1H, d, J1,2 = 5.0 Hz, H-1). 
 
Synthesis of 6-azido-6-deoxy-D-galactopyranose   
The previously made 1,2,3,4-di-O-isopropylidene-6-azido-6-deoxy-α-D-galactopyranose 
(4.04 g, 14.1 mmol) was dissolved into hydrochloric acid (HCl, 0.6 M, 551 mL) and 
warmed to 80 °C. After 18 h, the pH was adjusted to 7 with solid sodium bicarbonate (0.21 
g). The reaction mixture was lyophilized and purified by flash chromatography (20% 
MeOH/DCM) to yield a white solid (2.76 g, 95%). 1H NMR (500 MHz, D2O) δ 3.33-3.65 
(m, 3.4H, H-3, H-6, H-6’, H-6, H-6’, H-2), 3.75-3.83 (m, 1.3H, H-5, H-3, H-2), 
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3.87 (m, 0.7H, H-4), 3.92 (m, 0.3H, H-4), 4.15 (m, 0.3H, H-5), 4.56 (d, 0.7H, J1-2 = 8.2 
Hz, H-1), 5.21 (d, 0.3H, J1,2 = 3.6 Hz, H-1). 
 
Synthesis of 1,2,3,4-tetra-O- acetyl-6-azido-6-deoxy-α-D-galactopyranose 
Acetic anhydride (14.7 mL) was added to a round bottom flask containing the previously 
synthesized 6-azido-6-deoxy-D-galactopyranose (2.76 g, 13.5 mmol) at 0 °C under argon. 
Boron trifluoroetherate (3.5 mL, 1.8 eq) was added dropwise to the suspension. After 5 h 
at RT, the reaction mixture was diluted with DCM (200 mL) and extracted with sat. 
NaHCO3 (3 x 200 mL) and brine (100 mL). The organic layer was dried with MgSO4, 
concentrated in vacuo, and purified by flash chromatography (30% EtOAc/Hex) to yield a 
white solid (4.29 g, 80%). 1H-NMR (500 MHz, CDCl3) δ 2.01 (3H, s, CH3COO), 2.03 (3H, 
s, CH3COO), 2.17 (3H, s, CH3COO), 2.18 (3H, s, CH3COO), 3.19 (1H, dd, H-6’), 3.42 
(1H, dd, J6,6’ = 12.4 Hz, H-6), 4.23 (1H, br dd, J5,6 = 7.4 Hz, J5,6’ = 5.4 Hz, H-5), 5.33-5.34 
(2H, m, H-2, H-3), 5.48 (1H, d, J < 1 Hz, H-4), 6.40 (1H, s, H-1). 
 
 
Synthesis of 2,3,4-tri-O-acetyl-6-azido-6-deoxy-α-D-galactopyranose 
A solution of 1,2,3,4-tetra-O- acetyl-6-azido-6-deoxy-α-D-galactopyranose (3.89 g, 10.4 
mmol) in DMF (80 mL) and N,N-diisopropylethylamine (DIPEA, 15.3 mL, 8.6 eq) was 
stirred with ammonium acetate crystals (3.24 g, 4 eq) at RT for 2 days. After 2 days, the 
reaction mixture was decanted from the ammonium acetate crystals into a separatory funnel 
and diluted with DCM (260 mL). The mixture was then extracted with sat. NaHCO3 (170 
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mL) and water (80 mL), dried with MgSO4, concentrated in vacuo, and purified by flash 
chromatography (1:1 EtOAc/Hex) to yield a clear oil (2.76 g, 80%). 1H-NMR (500 MHz, 
CDCl3) δ 1.95 (3H, s, CH3COO), 2.06 (3H, s, CH3COO), 2.12 (3H, s, CH3COO), 3.20 
(0.83H, dd, H-6’), 3.24 (0.17H, dd, H-6’), 3.42 (0.83H, dd, J6,6’ = 12.8 Hz, H-6), 3.51 
(0.17H, dd, J5,6 = 8.0 Hz, J6,6’ = 12.8 Hz, H-6), 3.83 (ddd, 0.17H, J4,5 = 0.7 Hz, J5,6 = 7.6 
Hz, J5,6’ = 5.0 Hz, H-5), 4.08 (0.17H, d, OH), 4.27 (0.83H, br, OH), 4.37 (0.83H, dd, J5-
6 = 4.4 Hz, J5-6’ = 8.3 Hz, H-5), 4.72 (0.17H, t, J1,OH = J1,2 = 6.8 Hz, H-1), 4.98-5.06 
(0.34H, m, H-, H-2), 5.12 (0.83H, dd, J2,3 = 10.0 Hz, H-2), 5.32-5.38 (1H, m, H-, H-
3), 5.49 (0.83H, s, H-4). 
 
Synthesis of 2,3,4-tri-O-acetyl-6-azido-6-deoxy-α-D-galactopyranosyl phosphite 
mono-Et3N salt 
The previously synthesized 2,3,4-tri-O-acetyl-6-azido-6-deoxy-α-D-galactopyranose (2.76 
g, 8.3 mmol) was dissolved in THF (11 mL) and dioxane (22 mL) and stirred at 0 °C. 
Triethylamine (Et3N, 1.77 mL, 1.55 eq) and a solution of 2-chloro-1,3,2-
benzodioxaphosphorin-4-one (1.69 g, 1 eq)  in THF (5.5 mL) was then added to the mixture 
and stirred for 35 min at 0 °C. The reaction was quenched with the addition of water (5 
mL) and concentrated in vacuo. The concentrate was then redissolved into THF (110 mL) 
and the precipitant that formed was separated by filtration. After concentration of the 
filtrate, the crude compound was purified by column chromatography (gradient of 5% 
MeOH/DCM to 20% MeOH/DCM) to afford the product phosphite as a white solid (2.77 
g, 84%). 1H-NMR (500 MHz, CDCl3) δ 1.32 (9H, t, (CH3CH2)3NH+), 1.96 (3H, s, 
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CH3COO), 2.07 (3H, s, CH3COO), 2.16 (3H, s, CH3-COO), 3.19 (6H, q, J = 7.3 Hz, 
(CH3CH2)3NH+), 3.28 (1H, dd, H-6’), 3.48 (1H, dd, J6,6’ = 12.8 Hz, H-6), 4.40 (1H, ddd, 
J5,6 = 7.4 Hz, J5,6’ = 5.5 Hz, H-5), 5.15 (1H, ddd, J2,4 = 1.8 Hz, H-2), 5.36 (1H, dd, J2,3 = 
10.8 Hz, H-3), 5.46 (1H, br dd,  J3,4 = 3.3 Hz, J4,5 = 1.1 Hz, H-4), 5.82 (1H, dd, J1,2 = 3.4 
Hz, JH,P = 8.8 Hz, H-1), 6.81 (1H, m, P-H). 
 
Synthesis of 2,3,4-tri-O-acetyl-6-azido-6-deoxy-α-D-galactopyranosyl phosphate 
mono-Et3N salt 
The previously synthesized phosphite (2.77 g, 5.6 mmol) was dissolved into THF (100 mL) 
and stirred with cation exchange resin (Dowex 50W-X8 H+ form) for 1 h at RT. The resin 
was filtered out and the filtrate was concentrated in vacuo. The resulting oil was then 
dissolved with THF (96 mL) and t-BuOOH (2.2 mL of 5.5 M solution in undecane, 2 eq) 
and iodine (19.3 mg, 0.01 eq) were added under argon. After stirring for 24 h at RT, the 
reaction mixture was neutralized with Et3N (0.8 mL, 2.05 eq) and concentrated in vacuo. 
The concentrate was purified by a C18 reverse-phase column (water as eluent) to give the 
phosphate product as an oil (700 mg, 24%). 1H-NMR (500 MHz, CD3OD) δ 1.32 (9H, t, 
(CH3CH2)3NH+), 1.97 (3H, s, CH3COO), 2.06 (3H, s, CH3COO), 2.16 (3H, s, CH3COO), 
3.17 (6H, q, J = 7.2 Hz, (CH3CH2)3NH+), 3.29 (1H, dd, H-6’), 3.50 (1H, dd, J6,6’ = 12.5 
Hz, H-6), 4.41 (1H, ddd, J5,6 = 6.2 Hz, J5,6’ = 7.1 Hz, H-5), 5.11 (1H, ddd, H-2), 5.40 (1H, 
dd, J2,3 = 10.9 Hz, H-3), 5.47 (1H, dd, J3,4 = 4.5 Hz, J4,5 < 1 Hz, J2,4 = 2.2 Hz, H-4), 5.74 
(1H, dd, J1,2 = 2.8 Hz, JH,P = 7.5 Hz, H-1). 
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Synthesis of uridine 5’-(2,3,4-tri-O-acetyl-6-azido-6-deoxy- α-D -galactopyranosyl) 
diphosphate bistriethylammonium salt     
4’-morpholine-N,N’-dicyclohexylcarboxamidinium (UMP-morpholidate, 1.02 g, 1.5 
mmol, 2 eq) and tetrazole (3.45 mL, 0.45 M in acetonitrile, 2 eq) were added to a round 
bottom and dried three times with pyridine in vacuo. In another round bottom, the 
previously synthesized phosphate (380 mg, 0.74 mmol) was also dried three times with 
pyridine in vacuo. After both were dry, the UMP-morpholidate and tetrazole were 
dissolved in dry pyridine (70 mL) and added to the dried phosphate. The mixture was then 
dried two more times with pyridine in vacuo. Dry pyridine (30 mL) was then added after 
the materials were dry and the reaction was stirred in the dark for 2 days under argon. After 
2 days, toluene was added and the mixture was concentrated in vacuo. After lyophilization, 
the product was purified on a semi-preparative HPLC C18-column (linear gradient for 10 
min from 90:10 water/MeCN to 50:50 water/MeCN with detection at 254 nm) to afford the 
product (270 mg, 40%). 1H-NMR (500 MHz, D2O) δ 1.29 (18H, t, (CH3CH2)3NH+), 1.99 
(3H, s,  CH3COO), 2.12 (3H, s, CH3COO), 2.19 (3H, s, CH3COO), 3.53 (1H, dd, J6-6’ = 
12.9 Hz, H-6gal), 3.41 (q, 12H, J = 7.3 Hz, (CH3CH2)3NH+), 4.16 (1H, ddd, J = 3.3 Hz, J = 
5.4 Hz, J5,5’ = 12.0 Hz, H-5’rib), 4.22-4.27 (2H, m, H-4rib, H-5rib), 4.31-4.36 (2H, m, H-2rib, 
H-3rib), 4.49 (1H, t, J5,6,6’ = 6.7 Hz, H-5gal), 5.19 (1H, dt, H-2gal), 5.35 (1H, dd, J2,3 = 10.7 
Hz, H-3gal), 5.50 (1H, d, J3,4 = 3.2 Hz, H-4gal), 5.77 (1H, dd, J1,2 = 3.5 Hz, J1,P = 7.7 Hz, H-
1gal), 5.94 (1H, d, J1,2= 3.5 Hz, H-1rib), 5.95 (1H, d, H-Dura), 7.95 (1H, d, JC,D = 8.1 Hz, H-
Cura). 
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Synthesis of uridine 5’-(6-azido-6-deoxy-a-D-galactopyranosyl) diphosphate 
bistriethylammonium salt 
The previously synthesized uridine 5’-(2,3,4-tri-O-acetyl-6-azido-6-deoxy- α-D -
galactopyranosyl) diphosphate bistriethylammonium salt (0.270 g, 0.29 mmol) was 
dissolved into methanol (20 mL) at 0 °C. An aqueous solution of NH4HCO3 (27 mL, 0.1 
M) and Et3N (1.1 mL, 26 eq) was added to the mixture and stirred for 23 h at 0 °C. After 
23 h, the solution was kept at 0 °C, diluted with water (120 mL), and the pH was adjusted 
to 7.5 with Dowex 50W-X8 H+ form resin. The resin was removed by filtration and the 
resin was washed with water (60 mL). After lyophilization of the filtrate, the product was 
purified by semi-preparative HPLC C18-column (linear gradient for 10 min from 95:5 
water/MeCN to 60:40 water/MeCN with detection at 254 nm) to afford the final product 
as a clear white solid (130 mg, 79%). 1H-NMR (500 MHz, D2O) δ 1.24 (18H, t, 
(CH3CH2)3NH+), 3.17 (12H, q, J = 7.3 Hz, (CH3CH2)3NH+), 3.42 (1H, dd, J5,6’ = 6.1 Hz, 
H-6’gal), 3.53 (1H, dd, J5,6 = 7.2 Hz, J6,6’ = 12.7 Hz, H-6gal), 3.75 (1H, dt, H-2gal), 3.88 (1H, 
dd, J2,3 = 10.3 Hz, H-3gal), 3.96 (1H, d, J3,4 = 3.2 Hz, H-4gal), 4.17-4.26 (4H, m, H-4rib, H-
5gal, H-5rib, H-5’rib), 4.32-4.36 (2H, m, H-2rib, H-3rib), 5.59 (1H, dd, J1,2 = 3.6 Hz, J1,P = 7.3 
Hz, H-1gal), 5.93-5.97 (2H, m, H-1rib, H-Dura), 7.94 (1H, d, JC,D = 8.2 Hz, H-Cura). 31P NMR 
(121.5 MHz, D2O) δ -13.00 (1P, d, JP,P = 21.0 Hz, P-rib), -11.26 (1P, d, JP,P = 20.7 Hz, P-
gal). 
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